

CURRICULUM VITAE

Scott Avard MacDiarmid, MD, FRCPSC

Alliance Urology Specialists
509 N Elam Ave., 2nd Floor
Greensboro, NC 27403
Telephone: 336 274 1114
Email: smacdiarmid@allianceurology.com

PERSONAL INFORMATION:

Birthplace and Date: Moncton, New Brunswick, Canada
November 27, 1960

Citizenship: Canada and United States (2006)

Marital Status: Married

Spouse's Name: Andrea

Children: Lindsey

EDUCATION:

1981 Dalhousie University
Halifax, Nova Scotia, Canada
B.S.

1985 Dalhousie University
Halifax, Nova Scotia, Canada
M.D.

POSTDOCTORAL

Internship:

1985-86 Rotating
Dalhousie University
Halifax, Nova Scotia, Canada

Residency:

1987-91 Urology
Dalhousie University
Halifax, Nova Scotia, Canada

Fellowships:

1991-1992 Reconstructive Urology and Urodynamics
Duke University Medical Center
Durham, North Carolina

Fellowships continued

:

- | | |
|------|--|
| 1993 | Reconstructive Urology and Urodynamics
University of Otago
Christchurch, New Zealand (9 months) |
| 1993 | Neuro-Urology, Reconstructive Urology
Lodgemoor Spinal Unit, University of Sheffield
Sheffield, England (4 months) |

PROFESSIONAL LICENSURE:

North Carolina Medical License # 2003-00648

SPECIALTY CERTIFICATION:

- | | |
|-----------------|---|
| September, 1991 | Fellow, Royal College of Physicians and Surgeons of Canada |
| February, 1996 | The American Board of Urology # 11273
Recertified: November, 2004
Recertified: August, 2013 |
| August, 2013 | Subspecialty certification: Female Pelvic Medicine and
Reconstructive Surgery (FPM-RS) |

EMPLOYMENT:

Academic/Professional Appointments:

- | | |
|--------------|---|
| 2015-Present | Clinical Associate Professor
Department of Urology
The University of North Carolina
Chapel Hill, NC |
| 2006-Present | Director Bladder Control and Pelvic Pain Center
Alliance Urology Specialists
Greensboro, NC |
| 2003-July 06 | Associate Professor of Surgery (Urology)
Department of Urology
Wake Forest University School of Medicine
Winston-Salem, NC |
| | Head
Reconstructive Urology and Urodynamics |

Director
Wake Forest University Continence Center

1999-2003 Associate Professor
Department of Urology
University of Tennessee
Memphis, TN

Head
Section of Urodynamics and Neuro-urology

Director
UT Bladder Control and Pelvic Pain Center

Service Chief
Methodist University Hospital

Faculty Urologist
UT Medical Group
Department of Urology

Deputy Research Director and Primary Investigator
Raines-Cox Urology Institute
Memphis, TN

1994-1999 Associate Professor
Department of Urology

Head
Section of Urodynamics and Neuro-urology

Director
UAMS Incontinence Center

Vice Chief
Section of Pediatric Urology

Medical Director of Urology Clinic
University of Arkansas for Medical Sciences

Director
Urology Spina Bifida Clinic
Arkansas Children's Hospital

OTHER PROFESSIONAL APPOINTMENTS AND INSTITUTIONAL SERVICE:

Hospital Affiliations:

2006- present Moses Cone Health System
Greensboro, NC

2003-2006 Attending Urologist
North Carolina Baptist Hospitals, Inc.
Winston-Salem, North Carolina

Editorial Work:

May 1997-Present	Reviewer Journal of Urology
October, 1999-Present	Reviewer Urology
March, 2000-Present	Reviewer World Journal of Urology
May, 2003-Present	Reviewer International Urogynecology Journal
January 2003 – Present	Reviewer: The Female Patient
May 2003 – Present	Editorial Board Member: The Female Patient
February 2005- Present	Reviewer: Drugs
May 2005 -Present	Reviewer: TheScienticWorld
September 2004 - Present	Reviewer: Neurourology and Urodynamics
September 2007- Present	Reviewer: International Journal of Clinical Practice

Advisory Board:

1996	Surgical Services Board University of Arkansas for Medical Sciences
1998	Advisory Board Women's Health Care Center University of Arkansas for Medical Sciences

Committees:

1996	Revitalization Committee for the Ambulatory Care Center University of Arkansas for Medical Sciences
1996	Practice Development Committee University of Arkansas for Medical Sciences
1997	Nominating Committee for the Group Practice Executive Committee University of Arkansas for Medical Sciences

1998	Advisory Committee for the Arkansas Foundation for Urologic Disease “ARFUD” Board of Directors
	Search Committee for replacement for Associate Dean for Administration
1998	Obstetrics/Gynecology Chair Search Committee University of Arkansas for Medical Sciences
2003	Germantown Medical Executive Committee
2005	CPOE Committee for Surgery
2008	Board of Trustees, Urologic Health Foundation (UHF)
2009-Present	Surgical Services Committee, Cone Health

PROFESSIONAL MEMBERSHIPS:

American Urological Association
North Carolina Urological Association
Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction
South Eastern Section of the American Urological Association – Active Member
North Carolina Medical Society
Sigma Phi Chi Medical Fraternity
American Medical Association

HONORS AND AWARDS:

1978	Highest Academic Achievement Award: Math, Science, and English Moncton High School New Brunswick, Canada
1978	Governor General’s Medal for Highest Academic Achievement Moncton High School New Brunswick Canada
1991	Recognized by Dalhousie University for “Playing a Significant Role in the Teaching of Medical Students”
1995	Recognized by University of Arkansas for Medical Sciences for “Dedication And Support of UAMS Continuing Medical Education Outreach Program”
1997	Red Sash Award - awarded by senior class of 1997 at University of Arkansas College of Medicine
1998	Best Doctors in Arkansas Urinary Incontinence

- 1998 Best Poster: *Treatment of Post Radical Prostatectomy Bladder Neck Contractures With a New Transurethral Balloon Dilatation Catheter.*
16th World Congress of Endourology and SWL
New York, New York
- 1998 Essay Finalist: *Treatment of Post Radical Prostatectomy Bladder Neck Contractures With a New Transurethral Balloon Dilatation Catheter.*
South Central Section Meeting
American Urological Association
Cancun, Mexico
- 1999 Best Doctors in America
- 2001 Life Member of the National Registry of Who's Who published in 2001 edition #164608
- 2001-2002 America's Registry of Outstanding Professionals
- 2002 Service Chief, Methodist Hospital
- 2002 Memphis Best Doctors, MD News, July
- 2005 Highlight Abstract for Publication Neurourology and Urodynamics
Urinary Incontinence and Incident Disability in Community Dwelling Older Women
Joint Annual Meeting of the Society for Urodynamics and Female Urology and the International Society of Pelvic Neuromodulation
Orlando, Florida
- 2005 Blue Ribbon Prize Winner
Flexible Dosing of Extended-Release Oxybutynin Improves Treatment Outcomes for Urge Incontinence
The 53rd Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
San Francisco
- 2006 Medscape Editor's Top Picks
Featured Specialty: Urology
Lower Urinary Tract Symptoms in Men: A Shifting Paradigm
Video Panel Discussion: Moderator- SA MacDiarmid
Medscape Urology
- 2006 Fellowship Award for Medical Student Research Training Program
Supported by the NIH Short Term Research Training of Medical Students grant award
- 2010-15 Best Doctors in America Nomination.
- 2009-2015 Best Doctors in NC Nomination

Major Development Awards

Program Development Award from UAMS in support of UAMS Incontinence Center (1985): \$400,000.00.

Program Development Award from Chancellor in support of UAMS Incontinence Center (1997-1998): \$1,400,000.00.

Program Development Award from Don Reynolds Center on Aging in support of satellite UAMS Incontinence Center (1999): \$240,000.00.

SCHOLARSHIPS:

1982	Academic Entrance Scholarship Medical School
1981	Academic Scholarship B. SC.
1980	Academic Scholarship B. SC.
1979	Academic Scholarship B. SC.

VISITING PROFESSORSHIPS/GUEST LECTURESHIPS/MODERATOR:

1. Guest lecturer, Charleston Urologic Society, Charleston, North Carolina, November, 1994.
2. Clinical preceptor, *The Artificial Urinary Sphincter: Technical Aspects and Troubleshooting*, American Medical Systems, May, 1995.
3. Visiting Professor, Department of Urology, Louisiana State University School of Medicine, Shreveport, Louisiana, January, 1996.
4. Moderator, Urethral Reconstruction, South Central Section, American Urological Association, Vail, Colorado, September, 1996.
5. Clinical Preceptor, *The Artificial Urinary Sphincter: Technical Aspects and Marketing*, American Medical Systems, April, 1996.
6. Moderator, Incontinence Symposium: *The Artificial Urinary Sphincter.*, Duke University, Durham, North Carolina, August, 1997.
7. Moderator, Bladder Dysfunction, South Central Section, American Urological Association, Cancun, Mexico, November, 1998.
8. Consultant in Round Table Discussions, *Current & Future Trends in Urinary Incontinence*, American Medical Systems, April, 1998.
9. Consultant in Round Table Preparation of Nationwide CME Program: *Men's Health Issues*, Pfizer, June, 1998; August, 1998.
10. Visiting Professor, Canadian Urological Association Meeting, Topic: *Post-Prostatectomy Incontinence*, Halifax, Canada, June, 1998.

11. Visiting Professor, Canadian Urological Association Meeting, Topic: *Management of Urge and Mixed Stress/Urge Incontinence*, Halifax, Canada, June, 1998.
12. Moderator, Nationwide Tele net (CME): *Urgency/Frequency Syndrome and Urge Incontinence*. Sponsor: University of South Dakota School of Medicine, Sioux Falls, South Dakota, August, 1998.
13. Moderator, Incontinence Symposium: *The Artificial Urinary Sphincter*, San Diego, California, October, 1998.
14. Moderator, Incontinence Symposium: *The Artificial Urinary Sphincter*, Duke University, Durham, North Carolina, November, 1998.
15. Consultant, BPH Advisory Board, Phoenix, Arizona, Abbott Pharmaceuticals, February, 1999.
16. Moderator, Nationwide Teleconference – VA Hospitals (CME): *Male Urinary Incontinence & Benign Prostatic Hyperplasia*. Sponsor: GRECC, Minneapolis, Minnesota, March, 1999.
17. Moderator, Incontinence Symposium: *The Artificial Urinary Sphincter*, Los Angeles, California, February, 1999.
18. Moderator, Incontinence Symposium: *The Artificial Urinary Sphincter*, Duke University, Durham, North Carolina, April, 1999.
19. Consultant in Round Table Discussions: *Current and Future Trends in Urinary Incontinence*, American Medical Systems, April, 1999.
20. Keynote Speaker. *Balloon Dilatation of Urethral Strictures and Bladder Neck Contractures*, Urinary Tract Infection Advisory Board, Dallas, Texas, Ortho-McNeil, April, 1999.
21. Consultant, South Central Section Advisory Board. Medical Management of Urinary Incontinence, ALZA Pharmaceuticals, Dallas, May, 1999.
22. Keynote Speaker. *Overactive Bladder*. South Central Section Advisory Board. Medical Management of Urinary Incontinence, ALZA Pharmaceuticals, Dallas, May, 1999.
23. Urology and Symposium Chair, CME Round Table Program: *A Primary Provider's Search for an Approach to Bladder Control Problems*. Future publication in Veteran's Health System Journal (VHSJ). Coordinated by American MECCA, Chicago, June 25-26, 1999.
24. Moderator, Urethra & Testis, South Central Section, American Urological Association, Santa Fe, New Mexico, September, 1999.
25. Moderator, Nationwide Tele net (CME): *Overactive Bladder for Primary Care Physicians*: University of South Dakota School of Medicine, Sioux Falls, South Dakota, September, 1999.

26. Moderator, Incontinence Symposium. *The Artificial Urinary Sphincter*, Duke University, Durham, North Carolina, October, 1999.
27. Moderator, Nationwide Tele net (CME): Overactive Bladder Update for Specialists in Urology: University of South Dakota School of Medicine, Sioux Falls, South Dakota, November 1999.
28. Advisor, Abbott Pharmaceuticals- “Brainstorming Clinical Pharmacology Studies, ABT-980 for BPH,” February, 2000.
29. Advisor, Abbott Pharmaceuticals-“Development of Symptom Questionnaire for Incontinence,” February, 2000.
30. National Advisory Board Member, Ortho-McNeil Pharmaceuticals, February, 2000-present.
31. Moderator, Statewide Tele-Conference- “BPH for Primary Care Physicians,” Arkansas, March, 2000.
32. Moderator, Statewide Tele-Conference-“Overactive Bladder,” Arkansas, March, 2000.
33. Moderator, Nationwide Tele-Conference-“A Practical Approach to Patient with BPH”, April, 2000.
34. Moderator, Nationwide Tele-Conferences, “Overactive Bladder,” ALZA Pharmaceuticals, May-July, 2000.
35. Moderator, Incontinence Symposium. *The Artificial Urinary Sphincter*, Duke University, Durham, NC, July, 2000.
36. Moderator, Incontinence Symposium. *The Artificial Urinary Sphincter*. Duke University, Durham, NC, August, 2000.
37. Keynote Guest Lecturer. Bladder Research Day. A Research Symposium. Dalhousie University, Halifax, Nova Scotia, Canada, October, 2000.
38. Moderator, Incontinence Symposium. *The Artificial Urinary Sphincter*. Duke University, Durham, NC, March, 2001.
39. Keynote Guest Lecturer. Educating the Primary Care Physician in the Treatment of Overactive Bladder. ALZA Pharmaceuticals National Training Meeting. Pasadena, CA, April, 2001.
40. Moderator, Incontinence Symposium. *The Artificial Urinary Sphincter*. Duke University, Durham, NC, May, 2001.
41. Keynote Guest Lecturer. New Innovations in the Management of Overactive Bladder. SUNA Meeting. American Urologic Association, Anaheim, CA, June, 2001.
42. Keynote Guest Lecturer. Medical Management of Overactive Bladder. American Academy of Nurse Practitioners Annual Meeting, Orlando, FL, June, 2001.

43. Keynote Guest Lecturer. Educating the Primary Care Physician in the Treatment of Overactive Bladder. ALZA Pharmaceutical National Training Meeting, Boston, MA, July, 2001.
44. Keynote Guest Lecturer. Innovations in the Medical Management of Overactive Bladder. ALZA Pharmaceuticals National Training Meeting, New York, NY, July, 2001.
45. Moderator, Nationwide Tele-Conference, "Overactive Bladder," ALZA Pharmaceuticals, July-November, 2001.
46. Guest Speaker and Moderator. Educating the Primary Care Physician in the Treatment of Overactive Bladder. ALZA Pharmaceuticals National Training Meeting, Boston, MA, July, 2001.
47. Medical Advisory Board Meeting, Ortho-McNeil Pharmaceuticals, Ditropan XL. Nantucket, MA, August, 2001.
48. Faculty Reviewer, Duloxetine Primer: Overview of Stress Urinary Incontinence (SUI), the SUI Market, and the Duloxetine Compound, Eli Lilly's SUI Training Program. Eli Lilly Pharmaceuticals, August, 2001.
49. Guest Speaker, Incontinence Symposium: Maximizing Treatment of Overactive Bladder. Southeastern Region. Atlanta, GA, March, 2002.
50. Moderator, Regional Speaker's Training Meeting, Voiding Dysfunction and Pelvic Pain. Ortho-McNeil Pharmaceuticals. Phoenix, AZ, March, 2002.
51. Medical Advisory Board Meeting, Watson Pharma, Inc. Oxytrol. Atlanta, GA, April, 2002.
52. Moderator, Nationwide Tele-Conference, "Overactive Bladder," Ortho-McNeil Pharmaceuticals, April-September, 2002.
53. Consultant Urologist. Professional Desk-side Briefings (Family Circle, Fitness, Self, Health, Vogue, Glamour, Town & Country, Parenting, Parents, Cosmopolitan). New York City, NY, April, 2002.
54. Keynote Speaker, Maximizing Treatment of Overactive Bladder. SUNA Meeting. American Urological Association. Orlando, FL, May, 2002.
55. Moderator, Incontinence Symposium. The Artificial Urinary Sphincter. Duke University Medical Center. Durham, NC, May, 2002.
56. Guest Speaker, Overactive Bladder: Current Challenges-Future Solutions. Watson Pharma, Inc. Meeting. Boston, MA, June, 2002.
57. Guest Speaker and Moderator, Overactive Bladder: Key Issues and Treatment Options. Watson Pharma, Inc. Rosemont, IL, June, 2002.
58. Moderator/Speaker Trainer, Urinary Incontinence Symposium. Atlanta, GA, July, 2002. Ortho-McNeil Pharmaceuticals.

59. Guest Lecturer, Women with Bladder Dysfunction: The Art of Patient Management. Baylor College of Medicine, Orlando, FL, July, 2002.
60. Guest Speaker, The Role of the Primary Care Physician in the Treatment of Overactive Bladder. Denver, CO, July, 2002. Ortho-McNeil Pharmaceuticals.
61. Guest Speaker, Establishment of a Continence Center. Denver, CO, July, 2002. Ortho-McNeil Pharmaceuticals.
62. Moderator, Central/North Central Region Consultant Meeting. Toronto, Canada, August, 2002.
63. Strategic Task Force Member, Bladder Matters Health Initiative. August, 2002. Ortho-McNeil Pharmaceuticals.
64. Guest Speaker, The Role of Pharmacokinetics in the Treatment of Overactive Bladder. Pri-med Symposium. Chicago, IL, September, 2002. Watson Urology.
65. Moderator, Nationwide Teleconference, "Overactive Bladder." Ortho-McNeil Pharmaceuticals, September-November, 2002.
66. Steering Committee Member. Bladder Matters Health Initiative. Ortho-McNeil Pharmaceuticals November, 2002.
67. Guest Physician. The Role of Botox in the Treatment of Urinary Incontinence. Methodist Le Bonheur Healthcast, Memphis, TN, November, 2002.
68. Faculty Speaker. Bladder Health Nurse Advisory Board. Philadelphia, PA, November 2002.
69. Oxytrol Scientific Advisory Board Member. Palm Beach, FL. January, 2003. Watson Urology.
70. Moderator, Nationwide Teleconference, "Bladder Matters Speaker Training," April, 2003. Ortho-McNeil Pharmaceuticals.
71. National Advisory Board Member Meeting. The Role of Tropsium Hydrochloride in the Treatment of Overactive Bladder. Miami, FL, November, 2002. Indevus Pharmaceuticals.
72. Guest Lecturer. Management Strategies for the Overactive Bladder. Society of Urologic Nurses and Associates (SUNA) 34th Annual Meeting. San Antonio, TX, April, 2002.
73. Moderator, Nationwide Teleconference, "Bladder Matters: Clinical Insights on Urologic Health," April-May, 2003. Ortho-McNeil Pharmaceuticals.
74. Steering Committee Member. The Public Health Implications of Urogenital Disease: A Focus on Overactive Bladder. Washington, DC, January, 2003.
75. Moderator. Bladder Matters: Clinical Insights on Urologic Health Meeting. Hollywood, CA, January, 2003. Ortho-McNeil Pharmaceuticals.

76. Advisory Board Member. Bladder Matters: Clinical Insights on Urologic Health Consultant Board Meeting. San Francisco, CA, March, 2003. Ortho-McNeil Pharmaceuticals.
77. National Advisory Board Member Meeting. Darifenacin as a Treatment of Overactive Bladder, April, 2003. Novartis
78. Faculty/Guest Speaker Canadian National Advisory Board Meeting. Ditropan XL. Kingston, Jamaica, May, 2003
79. Consultant. Treatment of Overactive Bladder in Special Patient Populations. Montreal, Canada. August, 2003. Med Reviews, LLC.
80. Advisory Board Member. OAB Advisory Meeting. Charleston, SC. August, 2003. McNeil Consumers & Specialty Pharmaceuticals.
81. Moderator. Elmiron Regional Advisory Board Meeting. October, 2003. Cincinnati, OH. Ortho-McNeil Pharmaceuticals.
82. Moderator. Nationwide Teleconference. Oxytrol: Scientific Data, Clinical Experience, and Practical Solutions. September, 2003 – November, 2003. Watson Pharma, Inc.
83. Guest Lecturer. Treatment Options for OAB. Women’s Health Consultants’ Forum. December, 2003. Phoenix, Arizona. Watson Pharma, Inc.
84. Advisory Board Member. Ditropan XL National Advisory Board Meeting. December, 2003. Chicago, Illinois.
85. Guest Interview. Urinary Incontinence. Winston-Salem, NC. December, 2003.
86. Guest Interview. Urinary Incontinence. Winston-Salem, NC. December, 2003. CBS Affiliate.
87. Faculty. Regional Leadership Series. Overactive Bladder. February, 2004. Key Biscayne, Florida. Pfizer, Inc.
88. Moderator, New Perspectives on Chronic Pelvic Pain Syndrome. Atlanta. March, 2004. Ortho-McNeil Pharmaceuticals.
89. Moderator. Nationwide Teleconference. (CD Rom) “Bladder Matters: New Perspective on Pelvic Health Management.” April, 2004. Ortho-McNeil Pharmaceuticals.
90. Global Advisory Board. Enablex (Darifenicen). Dublin, Ireland. April, 2004. Novartis.
91. Moderator. Nationwide Teleconference. Oxytrol: Treatment of OAB. April, 2004 – September, 2004. Watson, Pharma, Inc.
92. Moderator. Bladder Matters Regional Advisory Board Meeting. Chapel Hill, NC. May, 2004. Ortho-McNeil Pharmaceuticals.

93. Advisor. 2004 Bladder Matters Consultant Newsletter Series. Ortho-McNeil Pharmaceuticals.
94. Key Note Speaker. "Maximizing the Treatment of Overactive Bladder." Mid- West Geriatrics Symposium: The Aging Bladder. Champagne, Illinois. May, 2004.
95. Moderator. Bladder Matters Regional Advisory Board Meeting. Plymouth, MN. May, 2004. Ortho-McNeill Pharmaceuticals.
96. Advisor. Fesoterodine US Roundtable Meeting. San Francisco, CA. May, 2004. Schwarz Pharma.
97. Course Director. New Treatment for the Overactive Bladder. American Urological Association Meeting. San Francisco, CA. May, 2004.
98. Post-Graduate Course Faculty. Advancements and New Frontiers in Incontinence and Voiding Dysfunction. American Urological Association Meeting. San Francisco, CA. May, 2004.
99. Faculty. New Strategies for the Treatment of OAB: Vision, Performance and Future Directions. "Towards Optimal Pharmacology of OAB Therapy". International Consultation on Incontinence, Satellite Symposium, Monaco, June, 2004.
100. Advisor. Oxytrol Regional Consultant Meeting. "Why Transdermal Oxybutynin?"; How to Educate Physicians on the Oxybutynin Transdermal System and Related Issues". Providence, Rhode Island, July 2004.
101. Key Note Speaker. South Carolina Urological Association Annual Meeting. "Mid-urethral Slings". Columbia, SC. September, 2004.
102. Faculty. Oxytrol Nationwide Teleconference. Overactive Bladder: New Therapeutic Options. September, 2004.
103. Faculty. Overactive Bladder: The Path to Successful Outcomes. A CME Satellite Symposium. "Maximizing Anticholinergic Therapy for OAB: Has the Ceiling Been Reached? The 27th Congress of the Society of International Urologists. Honolulu, Hawaii. October, 2004.
104. Key-Note Speaker. Mid-urethral Slings. The 28th Annual Frank R. Lock OB/GYN Symposium. Wake Forest University. Winston-Salem. October, 2004.
105. Faculty. Oxytrol Regional Consultant Meeting. "Efficacy and Safety of Oxytrol". Chicago, Illinois, October, 2004.
106. Co-Chairman. Ditropan XL Primary Care Advisory Board. "Management Strategies for OAB". Philadelphia, Pennsylvania, October, 2004.
107. Key Note Speaker. Nationwide Canadian Virtual Symposium. "A Clinical Review and Evidence-Based Introduction to Oxytrol". Toronto, Canada, November, 2004.
108. Advisor. Odyssey/Indevus National Advisory Board Meeting. Miami, Florida, October, 2004.

109. Faculty. GlaxoSmithKline Overactive Bladder Webcast Roundtable. November, 2004.
110. Advisor. Ditropan OTC Advisory Board Meeting. Philadelphia, Pennsylvania. January, 2005.
111. Faculty. NAFE Nationwide Teleconference. Overactive Bladder. New York, New York. January, 2005.
112. Advisor. Ditropan XL National Advisory Board Meeting. Dallas, Texas. January, 2005.
113. Visiting Professor. What's New in the Management of OAB? Department of Obstetrics and Gynecology. University of Tennessee. Memphis, Tennessee. February, 2005.
114. Faculty. Watson Pharma Regional Consultant Meeting. "Treating OAB with Oxytrol: A Clinical Review". Charleston, South Carolina. March, 2005.
115. Advisor. Watson Oxytrol Speaker's Update Meeting. Dallas, TX. Oct, 2005.
116. Guest speaker. OrthoUrology POA National Mtg Southeastern Region. Atlanta, GA. 2005
117. Guest speaker. OrthoUrology POA National Meeting Western Regions. Dallas, TX. 2005.
118. Advisor. Ditropan XL Advisory Board Meeting. Miami, FL. Jan, 2006.
119. Advisor. Astellans Urology Advisory Board. Miami, FL, Jan, 2006.
120. Faculty. Raising the Bar in the Management of OAB. Pittsburg, PA. March, 2006. (CME)
121. Faculty. Watson Pharma Regional Consultant Meeting. "Treating OAB with Oxytrol: A Clinical Review". Charleston, South Carolina. April, 2005.
122. Faculty. Detrol LA Regional Advisory Board Meeting. "The Role of Anticholinergics in Men with Lower Urinary Tract Symptoms". Miami, Florida. May, 2005.

123. Lecturer. Maximizing the Treatment of OAB. Department of Geriatrics. Wake Forest University. July, 2005.
124. Advisor. Fesoterodine Roundtable Meeting. Chicago. IL. July, 2005.
125. Speaker. Management of Overactive Bladder. First Annual Women's Health Symposium. Winston-Salem. Sept, 2005.
126. Faculty. Watson Pharma Regional Consultant Meeting. Charleston, SC. Sept, 2005.
127. Faculty. Medical Management of OAB. Kentucky Urologic Association Annual Meeting. Sept, 2005.

128. Faculty. Treatment of OAB: What do Patients Want and What Do Physicians Provide? 35th Annual Meeting of the International Continence Society. Montreal, Canada. Sept, 2005.
129. Presenter. What We Know About Flexible Dosing in the Treatment of OAB. 35th Annual Meeting of the International Continence Society. Montreal, Canada. Sept, 2005.
130. Faculty. Male OAB Advisory Board. Dallas, TX. Oct, 2005.
131. Faculty. Male OAB Advisory Board. Atlanta, GA. Oct, 2005.
132. Faculty. Clinical Effectiveness of OAB Management – Patient and Physician Perspectives. Medical Crossfire. North Eastern Section AUA. New York, NY. Oct, 2005.
133. Faculty. Clinical Effectiveness of OAB Management – Patient and Physician Perspectives. Medical Crossfire. South Central Section AUA. Southhamptom, Bermuda. Nov, 2005.
134. Presenter. Rethinking the Treatment of Men with Lower Urinary Tract Symptoms. Teleconference Series. Jan, 2006.
135. Faculty. Countdown to Continence Development Meeting. Miami, Florida. Feb, 2006.
136. Faculty. Male OAB Advisory Board. Miami, Florida. Feb, 2006.
137. Faculty. Overactive Bladder: Debating the Controversies in Therapeutic Management. Veritas Institute CME. Bond's Cay. Feb, 2006.
138. Presenter. Ditropan XL 2006 Promotional Speaker Training Web Conference. Feb, 2006.
139. Visiting Professor. Non-Surgical Treatment of Urethral Stricture Disease. McKay Department of Urology. Carolinas Medical Center. March, 2006.
140. Visiting Professor. Overactive Bladder: Maximizing Outcomes and New Areas of Research. Department of Urology. Royal Victoria Hospital, Montreal, Canada. March, 2006.
141. Faculty. Innovative Speaker Training Program- OAB in Men. Ann Arbor, Michigan. March, 2006.
142. Presenter. OAB-WRAP- A Leading Investigator, First Person Clinical Report. <http://clinicalwebcasts.com> (CME), 2006.
143. Speaker. Role of Antimuscarinics in the Management of Male LUTS. Washington Urological Associated Meeting. Washington, DC. Nov, 2006.
144. Visiting Professor. The role of anticholinergics and urodynamics in male LUTS. Department of Urology. Laval University. Quebec, Canada. Oct, 2006.

145. Visiting Professor. Maximizing the treatment of OAB. Department of Obstetrics and Gynecology. Laval University. Quebec, Canada. Oct, 2006.
146. Faculty. Enablex Continence Education Faculty Meeting. San Diego, CA. Jan, 2007.
147. Faculty. Enablex Train-The-Trainer Meeting. Coral Gables, FL. Jan, 2007.
148. Advisor. Global Advisory Council for Urology Indications. Clinical Liaison Group. Jan, 2007.
149. Advisor. MdConversation Advisory Meeting. Alberta, Canada. Jan, 2007.
150. Presenter. Emerging role of botulinum toxin in urology. MdConversation Advisory Board. Alberta, Canada. Jan, 2007.
151. Visiting Lecturer. Treating the Male Overactive Bladder Patient. Tampa Bay Urologic Society. Feb, 2007.
152. Faculty. Innovative Speaker Training on Overactive Bladder in Men. Groton, Connecticut. Feb, 2006.
153. Advisor. Esprit Leadership GUILD Advisory Board. Sunny Isles, FL. Feb, 2006.
154. Faculty. Overactive Bladder: Debating the Controversies in Therapeutic Management. Society for Urodynamics and Female Urology Winter Meeting. Bahamas. Feb, 2006.
155. Faculty. An Update on Pharmacological Treatments for OAB and Surgical Treatments for Incontinence and Pelvic Floor Prolapse. Department of Urology. Toronto, Canada. March, 2006.
156. Faculty. Challenges in Managing Urge Incontinence/OAB in the Elderly Patient: Evaluating Safety, Efficacy, and Side Effect Issues for Drug Therapy-Applying Landmark Trials to Clinical Practice. April, Miami, Florida. (CME)
157. Consultant. Expert Meeting- YM178 Urodynamic Study in Male LUTS Patients. Astellas Pharma. May, 2006.
158. Faculty. Countdown to Continence: The Pursuit of Dryness and Improved Quality of Life. CME Teleconference Series. 2006.
159. Faculty. Spotlight on Overactive Bladder-Integrating Trials into Clinical Practice. AUA Annual Meeting, Atlanta, GA. May, 06.
160. Moderator. Ditropan XL Flexible Dosing Rep Training module. June, 2006.
161. Faculty Speaker. CME Overactive Bladder Medical Center Briefing. Naval Medical Center, Portsmouth, VA. June, 2006.
162. Moderator. Ditropan XL Flexible Dosing Teleconferences. July-Dec, 2006.

163. Presenter. An Update for Managed Care Pharmacologic Management of Overactive Bladder- Teleconference Series. (CME) July, 2006.
164. Faculty Speaker. CME Overactive Bladder Medical Center Briefing. University of Kentucky Medical Center. Lexington, KY. Aug, 2006.
165. Advisor. Fesoterodine Working Group Meeting. Chicago, IL. August, 2006.
166. Advisor. Esprit Leadership Guild Advisory Board. Chicago, IL. August, 2006.
167. Speaker. A Clinical Update of Oxytrol and Transdermal Science. Oxytrol National Urology Consultants Meeting, Boston, MA. 2006.
168. Advisor. Oxytrol National Urology Consultants Meeting. Boston, MA. September, 2006.
169. Visiting Professor. Atlantic Canada Urology Update. Overactive Bladder-Current Concepts. Prince Edward Island, Canada. Sept, 2006.
170. Visiting Professor. Atlantic Canada Urology Update. Botulinum Toxin and the Overactive Bladder. Prince Edward Island, Canada. Sept 2006.
171. Presenter. Insights into the Pathophysiology and Therapeutic Management of Overactive Bladder. Georgetown University Hospital. Sept, 2006.
172. Consultant. Male Nexus OAB Consultant Meeting-Pfizer. Oct, 2006.
173. Moderator. Detrol LA Meet the Experts. Raleigh, NC. Nov, 2006.
174. Faculty. Urologic Health Foundation (UHF) National Steering Committee Meeting. Las Vegas, Nevada. Nov, 2006.
175. Presenter. Evaluating and treating male LUTS in primary care setting: an interactive case. Medscape, Nov, 2006. <http://www.medscape.com/viewprogram/6287>.
176. Faculty. Everything you need to know for OAB. Pri-Med. Orlando, FL. Oct, 2006.
177. Speaker. Improving the Management of Urinary Incontinence in the Older Adult: Evaluation the Clinical Literature. Kansas City, MS. Nov, 2007.
178. Presenter. Titration Investigation: Flexible Dosing in Overactive Bladder. Online Journal Club. Oct, 2007.
179. Faculty. Everything you need to know for OAB. Pri-Med. Washington, DC. Nov, 2006.
180. Faculty. The Urge to Define Urgency. Anaheim, CA. May, 2007.
181. Moderator. CLOVER Regional Advisory Board. Greensboro, NC. June, 2007.
182. Faculty. Sanctura Case Study Development Meeting. June, 2007.

183. Faculty. Oxytrol Urology Consultants Meeting. Huntington Beach, CA. Aug, 2007.
184. Faculty. Annual Fall Urology Symposium. Triangle Chapter SUNA. Greensboro, NC. Sept, 2007.
185. Faculty. Sharing Best Practices in Interstitial Cystitis Management. Atlanta, GA. Sept, 2007.
186. Advisor. Fesoterodine Advisory Board. New York, NY. Sept, 2007.
187. Participant. OAB iTheater Video Vignette. "IC CAST". 2007.
188. Faculty. Vesicare Peer to Peer Pipeline CD-ROM project. 2007.
189. Faculty. Vesicare Speaker Training Meeting. Orlando, FL. Aug, 2007.
190. Speaker. Treatment Options for OAB. Pri-Med. Charlotte, NC. Sept, 2007.
191. Visiting Professor. The Role of Anticholinergics and Urodynamics in Male LUTS. Department of Urology. University of Alberta. Winnepeg, Canada. Sept, 2007.
192. Faculty. Oxytrol Long-Term Care Consultants Meeting. Sunny Isles, FL. Oct, 2007.
193. Advisor. Elmiron Urology National Advisory Board. Coral Gables, FL. Nov, 2007.
194. Advisor/Moderator. Male OAB Advisory Board. New York, NY. Dec, 2007.
195. Faculty. Vesicare Speaker Training Meeting. Scottsdale, AZ. Dec. 2007.
196. Faculty. Medical Management of OAB. Pri-Med. Atlanta. Dec, 2007.
197. Advisor. Oxytrol National Urology Consultants Meeting: Innovative Treatment Approaches for OAB. Phoenix, AZ. Dec, 2007.
198. Presenter. Vesicare eDetail interactive. www.vesicarerx.com. 2008.
199. Faculty. Sanctura XR Speaker Training Meeting. Los Angeles, CA. Jan, 2008.
200. Presenter and Co-slide Developer. An Evidence-Based Presentation on Overactive Bladder Treatment in the Elderly. Teleconference Series. Archived version on www.oabelderly.com. Feb, 2008.
201. Speaker. Effectively Managing Urinary Incontinence in Your Long-Term Care Facilities. Salt Lake, Utah. March, 2008.
202. Presenter. OAB Cases 360. <http://www.ufound.org/OABCae360/>. 2008.
203. Faculty. Cleveland Clinic 8th Annual Female Pelvic Floor Disorders Symposium. Fort Lauderdale, FL. March, 2008.

204. Faculty. The OAB Sensation: Where Have We Been and Where Should We Be Going. Miami, FL. March, 2008.
205. Speaker. Tolterodine Efficacy in Sexually Active Women With OAB. Teleconference Series. March-May, 2008.
206. Speaker. Diagnosis and Treating Male Lower Urinary Tract Symptoms in the Primary Care Setting. Educational Concepts in Medicine CME. May, 2008.
207. Faculty. Sensation Investigation: Advancing Methods of Measuring Bladder Sensation in OAB. AUA Annual Meeting. Orlando, FL. May, 2008.
208. Faculty. Astellas Urology Pelvic Floor Disorders Advisory Board. Dallas, TX. May, 2008.
209. Advisor. Allergan National Advisory Board Meeting. Orlando, FL. May, 2008.
210. Consultant. Express Scripts Meeting. Minneapolis, MN. May, 2008.
211. Speaker/Faculty. The Role of Urodynamics in the Evaluation of OAB. 4th International Consultation on Incontinence. Paris, France. July, 2008.
212. Advisor. Watson Urology Advisory Board Meeting. Chicago, IL. July, 2008.
213. Speaker/participant. Treatment of Benign Prostatic Hyperplasia with Alpha-Blockers. Do Patient Age and Prostate Size Matter? Media Production, DAZ MEDIA. Chicago, IL. July, 2008.
214. Advisor. Watson Scientific OAB OxyGel Advisory Board Meeting. Chicago, IL. Aug, 2008.
215. Faculty. Allergan sub-analysis task force: sub-analysis by baseline UUI and Male OAB. Aug, 2008.
216. Advisor. Detrol/Fesoterodine OAB National Advisory Board. New York, NY. Aug, 2008.
217. Advisor. Sanofi Aventis National Urology Advisory Board Meeting. Chicago, IL. Sept, 2008.
218. Faculty. Diagnosis and Treatment of Male Lower Urinary Tract Symptoms in the Primary Care Setting. Practicing Physicians Exchange. Symposia Series 3. Oct, 2008.
219. Faculty. Management of Male LUTS in Primary Care Setting. Pri-Med. Oct, 2008.
220. Faculty. Male When Every Second Counts: The Benefits of Improved Warning Time for OAB Patients. SUNA Annual Meeting. Philadelphia, PA. Oct, 2008.
221. Advisor. Astellas Urology Pelvic Floor Disorders Advisory Board. San Francisco, CA. Nov, 2008.

222. Speaker. Helping Your OAB Patients Fight the Urge: Clinical Strategies to Reduce Urgency Severity. Teleconference Series. 2008.
223. Visiting professor. Overactive Bladder in Men. Division of Geriatric Medicine and Gerontology. Emory University. Nov, 2008.
224. Advisor/presenter. Watson National Urology Consultant Meeting. Palm Beech, FL. Dec, 2008.
225. Advisor/presenter. Watson National Urology Consultant Meeting. New York, NY. Dec, 2008.
226. Advisor. National Advisory Board. Watson Pharmaceuticals. Jan. 2009.
227. Presenter: A completely different approach to treating OAB. Henderson Nevada. Feb, 2009.
228. Advisor/presenter: Toviaz Speaker Training. New York, NY. Feb, 2009.
229. Faculty. Rapaflo Roundtable meeting. Dallas Texas. March, 2009.
230. Faculty. Toviaz Speaker Training. Dallas Texas. March, 2009.
231. Faculty. Medical Crossfire Clinical OAB. Las Vegas, Nevada. March, 2009.
232. Moderator. Sanctura XR Speaker Training. Miami, Florida. March, 2009.
233. Faculty. Sanctura XR Speaker Training. Los Angeles, California. March, 2009.
234. Faculty. Gelnique Speaker Training. Key Biscayne, Florida. April, 2009.
235. Faculty. Advances in the Pharmacologic Treatment of LUTS.. April, 2009.
236. Key note speaker. Gelnique Launch Meeting. Westin, Florida. May, 2009.
237. Moderator. Rapaflo Advisory Board. Tampa, Florida. May, 2009.
238. Faculty. Astellas Pelvic Floor Disorders Advisory Board. Chicago, IL. July, 2009.
239. Faculty. Uroplasty Medical Advisory Board. Minneapolis, MN. July, 2009.
240. Speaker. Alabama Medical Director Association's 15th Annual Conference. San Destin, Florida. July, 2009.
241. Speaker. Unique Perspectives in Urology. Miami, Florida. Oct, 2009.
242. Advisor. Urgency Forum Committee Meeting. London, England. Nov, 2009.
243. Faculty. Linking Experience, Advancement, and Data in Urological Research and Science Meeting. Dallas, Texas. March, 2010.
244. Faculty. Toviaz National Advisory Board. New York, NY. March, 2010.

245. *Advisore*. Astellas Global Urgency Advisor Board. Miami, Florida. March, 2010.
246. *Faculty*. Watson Urology Speaker Training. Ft. Laruderdale, Florida. April, 2010.
247. *Faculty*. Selective Nerve Stimulation Venture Scientific Data Review Meeting. San Francisco, California. May, 2010.
248. *Faculty*. Allergan National Leadership Council Meeting. San Francisco, California. May, 2010.
249. *Speaker*. Unique Perspectives in Urology. Chicago, IL. June, 2010.
250. *Key note speaker*. The People's Pharmacy National Broadcast. July, 2010.
251. *Advisor*. Bladder Health Advisory Board Meeting. Detroit, Michigan. July, 2010.
252. *Speaker*. Continence/Foot Care/Wound Care Symposium. Durham, NC. Sept, 2010.
253. *Speaker*. Eastern US POA Bayer Pharmaceutical Meeting. Ft. Lauderdale, Florida. Sept, 2010.
254. *Faculty*. Allergan NDO Steering Committee Meeting. New York, NY. Oct, 2010.
255. *Moderator*. Uroplasty Medical Advisory Board Meeting. Minneapolis, MN. Oct, 2010.
256. *Consultant*. Roth Capital Partners. Uroplasty, Inc. Dec, 2010.
257. *Faculty*. SXR 2011 Community Leadership Forum. Miami, Florida. Jan, 2011.
258. *Faculty*. Global Bladder Health. Miami, Florida. Jan, 2011.
259. *Faculty*. Toviaz National KOL Advisory Board. Miami, Florida. Jan, 2011.
260. *Speaker*. Speaker NewChannel.. Speakernewschannel.com. Feb, 2011.
261. *Faculty*. Toviaz Speaker Training. Atlanta, Georgia. Feb, 2011.
262. *Faculty*. Toviaz Speaker Training. Phoenix, AZ. Feb, 2011.
263. *Speaker*. Sanctura XR Web Training Series. Feb, 2011.
264. *Speaker*. Uroplasty National Sales Meeting. Washington, DC. May, 2011.
265. *Faculty*. Astellas Urology Franchise Mirabegron Advisory Board. Washington, DC. May, 2011.
266. *Speaker*. NC "Truth Wins" Sustainment Training, Pfizer. July, 2011.
267. *Faculty*. Allergan Urology NDO Advisory Board Meeting. Newport Beach, California. July, 2011.

268. Faculty. Segmentation Training Module, Astellas. Kindle Communications. Sept, 2011.
269. Faculty. Astellas OAB Advisory Board. San Francisco, California. Sept, 2011.
270. Speaker. PCE 2011 Symposia Series. LUTS in Men. Atlanta Georgia, Nov, 2011.
271. Speaker. PCE 2011 Symposia Series. LUTS in Men. Cleveland, Ohio, Dec, 2011.
272. Speaker. Allergan National Sales Meeting. Irvine, California. Dec, 2011.
273. Faculty. Botox NDO Advisory Board. New Orleans, LA. Feb, 2012.
274. Faculty. Toviaz National Advisory Board. New York, NY. March, 2012.
275. Faculty. Allergan Global Urology Meeting. Charleston, SC. March, 2012
276. Faculty. Allergan Global Strategic Marketing Meeting. New York, NY. April, 2012.
277. Advisor. Diabetes Urinary Function Screening Tool Steering Committee Meeting. New York, NY. April, 2012.
278. Faculty. Urology Advisory Board, Astellas. Atlanta, Georgia. May, 2012.
279. Faculty. Allergan Urology Advisory Board Meeting. Chicago, IL. June, 2012.
280. Speaker. Urodynamics Training WebEx. July, 2012.
281. Speaker. Toviaz NewsChannel-2012.
282. Faculty. Nocturia Content Development Meeting. Dallas, TX. August, 2012.
283. Faculty. Allergan Global Advisory Board Meeting. Miami, Florida. Sept, 2012.
284. Faculty. Allergan Urology Executive Council Advisory Board Meeting. Los Angeles, California. Oct, 2012.
285. Speaker. Evaluating and Treating Patients with OAB. Prim-Med. Raleigh, NC. Nov, 2012.
286. Consultant. BlueCross BlueShield. of North Carolina. Urology Round Table Meeting. Raleigh, NC. Feb, 2013.
287. Advisor. Regional Myrbetriq Speaker Program Advisory Board. New York, NY. April, 2013.
288. Speaker. Uroplasty National Sales Meeting. Phoenix, Arizona. May, 2013.
289. Speaker. BESIDE Study Investigator's Meeting. Boston, US. June, 2013.

290. Speaker. PCE 2013 Symposia Series. OAB-Strategies to Optimize Effective Therapy. Franklin, TN. June, 2013.
291. Faculty. Allergan Urology Executive Council Advisory Board Meeting. Dallas, Texas. Aug, 2013.
292. Visiting Professor. Department of Urology. University of Southern California. Los Angeles, CA. 2013
293. Speaker. Pri-Med Treating Patients with OAB. Raleigh, NC. Oct, 2013.
294. Faculty. Myrbetriq Patient Preference Pilot Study Protocol Advisory Board. Wheeling, IL. Nov, 2013.
295. Advisor. Medtonic Neuromodulation Therapy Experts Program. Minneapolis, MN. Nov, 2013.
296. Faculty. Astellas Global Medical Affairs OAB Portfolio Advisory Board Meeting. Miami, Florida. Feb, 2014.
297. Faculty. Allergan Executive Council Advisory Board Meeting. Miami, Florida. Feb, 2014.
298. Speaker. The Advanced Practice Therapy Experts Roundtable Webinar. Barriers to Treating OAB. June, 2014.
299. Speaker. Uroplasty Lunch and Learn. Driving Excellence for OAB. Webinar. July, 2014.
300. Speaker. Uroplasty Lunch and Learn. Driving Excellence for OAB. Webinar. Aug 2014.
301. Speaker. Uroplasty Lunch and Learn. Driving Excellence for OAB. Webinar. Sept 2014.
302. Speaker. Myrbetriq Rx Peer Insights ClinCast. Sept, 2014.
303. Speaker. OAB. Patient-Centered Approaches to Treating OAB. Washington, DC. Oct, 2014.
304. Speaker. Therapeutic OAB Update. PCE. Melville, NY. Oct, 2014.
305. Faculty. Astellas Global Advisory Board Meeting Phase IV Studies Myrbetriq. Jersey City, NJ. Nov, 2014
306. Speaker. Treatment Options for Bladder Control Problems. Webinar. Nov, 2014.
307. Speaker. The English Speaking Union of the US. When I Die, You Die. The Fall of the American Health Care System. Salisbury, NC. Nov, 2014.
308. Speaker. Uroplasty Lunch and Learn. Driving Excellence for OAB. Webinar. Jan, 2015.

309. Advisor. IC/BPS and Hunner's Lesions LRIS Treatment Advisory Board. Scottsdale, Arizona. Feb, 2015.
310. Speaker. Cogentix National Sales Meeting. Austin Texas. April, 2015.

PROFESSIONAL INTERESTS:

Funded Research:

1. Study to Evaluate the Impact of Viagra on Treatment Satisfaction in Male Patients with Sexual Dysfunction, 1997-98 (Pfizer) Primary Investigator.
2. A Double-blind Assessment of Tolterodine versus Tolterodine-Estring Ring in Treating Patients with Urge Incontinence, 1998 (Pharmacia-Upjohn) Primary Investigator.
3. Urodynamic Assessment of the Efficacy of Interstitial Laser Coagulation in the Treatment of BPH, 1998 (Indigo, Division of Johnson and Johnson) Co-investigator.
4. Physiologic Effects of PRMST and Testosterone in the Debilitated Elderly. Merit Review VA Grant, \$602,000.00, 5-year study Co-investigator.
5. A Dose-Range-Finding, Double-Blind Randomized, Placebo-Controlled Multi-Center, Active- Comparator Study to Determine the Effect of L-753099 in Postmenopausal Women with Predominantly Urge Urinary Incontinence, 1999 (Merck & Co., Inc.) Co-investigator.
6. Resiferotoxin Study: Protocol RTX-109, A Randomized, Parallel-Group, Double-Blind Placebo-Controlled Study Comparing the Safety, Tolerance, and Efficacy of RTX (reineratoxin) Topical Solution in Patients with Detrusor Hyperreflexia, (Afferon Corporation) Co-investigator.
7. ABT-980: Protocol M99-098. A Phase III Study of the Efficacy and Safety of ABT-980 in Subjects with Symptomatic Benign Prostatic Hyperplasia (Abbott Laboratories) Primary Investigator.
8. ABT-930: Protocol M00-166. A Double-Blind, Placebo-Controlled, Randomized, Cross-Over Study of the Effect of ABT-980 on Bladder Outlet Obstruction, Detrusor Instability and Bladder Function in Men with Symptomatic Bladder Outlet Obstruction (Abbott Laboratories) Primary Investigator.
9. Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer, Phase III Co-investigator.
10. Prospective, Randomized, Double-Blind Multi-Center, Comparative Trial to Evaluate Efficacy and Safety of Ciprofloxacin Once-Daily Modified Release (CIPRO MR) Tablets 1000 mg Versus Conventional Ciprofloxacin 500 mg Tablets BID in the 7-14 Day Treatment of Patients With Complicated Urinary Tract Infections or Acute, Uncomplicated Pyelonephritis, Sub-Investigator.

11. A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Safety and Efficacy of Dapoxetine HCL in the Treatment of Rapid Ejaculation, (ALZA Pharmaceuticals) Co-Investigator.
12. A Multi-Center Double Blind Randomized Placebo Controlled Parallel Group Study Accessing the Efficacy and Safety of MK-0869 in Post Menopausal Women with Urinary Incontinence (Merck) Co-Investigator.
13. Study. Design Consultant. Protocol CAPSS 292 – A Double-Blind, Randomized Parallel Group Trial of Ditropam XL (Oxybutymin Chloride) Extended Release Tablets or Placebo in Combination with Flomax (tamsulovin hydrochloride) for the Treatment of Lower Urinary Tract Symptoms (Ortho-McNeil Pharmaceuticals) 2004.
14. Collaborator. (Clinical Expert) RFA-RM-04-011: Development and Validation of a General Symptoms Checklist. Public Health Sciences. Wake Forest University School of Medicine, March 2003.
15. Protocol No. FE200486 CS21 08/2006 – 11/2007
Sponsor: Ferring Pharmaceuticals, Inc.
Title: An open-label, multi-centre, randomized, parallel-group study, investigating the efficacy and safety of Degarelix one month dosing regimens; 160 mg(40 mg/ml) and 80mg (20mg/ml), in comparison to Lupron depot[®] 7.5 mg in patients with prostate cancer requiring androgen ablation therapy.
Role: Sub-Investigator
16. Protocol No. AMGEN 20050103 08/2006 – 02/2010
Sponsor: Amgen, Inc.
Title: A randomized, double-blind, multicenter study of denosumab compared with Zoledronic acid (zometa[®]) in the treatment of bone metastases in men with hormone-refractory prostate cancer.
Role: Sub-Investigator
17. Protocol No. ANS C-04-05 08/2006 – 03/2008
Sponsor: Advanced Neuromodulation Systems
Title: A pilot study to evaluate sacral nerve root stimulation for the treatment of chronic pelvic pain due to interstitial cystitis.
Role: Sub-Investigator
18. Protocol No. H6D-MC-LVHK 07/2006 - 02/2008
Sponsor: Lilly
Title: A randomized, double-blind, placebo controlled, parallel design, multi-center study to evaluate the urodynamic effects of Tadalafil once a day for 12 weeks in men with signs and symptoms of Benign Prostatic Hyperplasia.
Role: Principal Investigator
19. Protocol No. REDEEM-AVO105948 08/2006 – 07/2010
Sponsor: GlaxoSmithKline
Title: A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of Dutasteride in extending the time to progression of low-risk, localized prostate cancer in men who are candidates for or undergoing expectant management.
Role: Sub-Investigator

20. Protocol No. UPC032006 09/2006 – 01/2009
Sponsor: Uroplasty
Title: Overactive bladder innovative therapy trial—OrBIT Trial, a randomized study comparing Urgent PC percutaneous tibial nerve stimulation with standardized pharmacologic therapy (Detrol LA) in reducing the frequency of urinary voids
Role: Principal Investigator
21. Protocol No. FE200486 CS21A 11/2006 – 12/2010
Sponsor: Ferring Pharmaceuticals, Inc.
Title: An open-label, multi-centre, extension study evaluating the long-term safety and tolerability of Degarelix one-month dosing regimen in patients with Prostate cancer requiring androgen ablation therapy.
Role: Sub-Investigator
22. Protocol No. FE200486 CS18 05/2007 – 10/2008
Sponsor: Ferring Pharmaceuticals, Inc.
Title: An Open-Label, Multi-Center, Randomized Parallel-Group Dose-Finding Study, Investigating efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in patients with Prostate Cancer requiring Androgen Ablation Therapy.
Role: Sub-Investigator
23. Protocol No. WX-2003-07-HR 07/2007 – 09/2012
Sponsor: Wilex
Title: A Randomized Double-Blind Phase III Study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence.
Role: Sub-Investigator
24. Protocol No. VEG101920 08/2007 – 08/2008
Sponsor: GlaxoSmithKline
Title: A study for the Detection and Characterization of Circulating Tumor Cells in the Peripheral Blood Circulation of Patients with Solid Tumor
Role: Sub-Investigator
25. Protocol No. A0221009 12/2007 – 05/2009
Sponsor: Pfizer
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fesoterodine as an “Add-On” Therapy in Men with Persistent Overactive Bladder Symptoms Under Monotherapy of Alpha Blocker for Lower Urinary Tract Symptoms.
Role: Principal Investigator
26. Protocol No. 905-CL-058 02/2008 – 09/2008
Sponsor: Astellas
Title: A Phase 2, Randomised, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to evaluate the safety of the co-administration of Solifenacin Succinate with 0.4mg Tamsulosin Symptoms (LUTS) and Bladder Outlet Obstruction
Role: Principal Investigator

27. Protocol No. A4091010 02/2008 – 05/2009
Sponsor: Pfizer
Title: A Phase 2, 16 Week, Multicenter, Randomized, Double-Blind Placebo Controlled, Parallel Group Proof of Concept Study Evaluating The Efficacy and Safety of PF-04383119 For the Treatment of Pain Associated with Interstitial Cystitis
Role: Sub-Investigator
28. Protocol No. UPC082008 SUmiT 10/2008 - 05/2009
Sponsor: Uroplasty
Title: A prospective, multi-center, randomized, intention-to-treat, double blinded, sham-Controlled study. Subjects are randomized 1:1 at enrollment to receive either Urgent PC or Sham intervention.
Role: Principal Investigator
29. Protocol No. UPC121908 STEP 01/2009 – 01/2009
Sponsor: Uroplasty
Title: This is a prospective, multicenter, open-label, observational, modified extension study of the SUmiT Trial, protocol UPC082008. The purpose of this study is to continue the treatment follow up of all positive responders of the Urgent PC treatment arm of the SUmiT Trial.
Role: Principal Investigator
30. Protocol No. SPI-612 03/2009 – 10/2012
Sponsor: Spectrum Pharmaceuticals, Inc.
Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical EOquin[®] as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer.
Role: Sub-Investigator
31. Protocol No. FE 200486 CS37 04/2009 – 04/2012
Sponsor: Ferring Pharmaceuticals, Inc.
Title: A Randomized, Controlled, Open-Label Trial of Degarelix Intermittent Therapy vs. Continuous Androgen Deprivation Therapy with Leuprolide or Degarelix in Patients with Carcinoma of the Prostate with Biochemical Failure after Localized Therapy.
Role: Sub-Investigator
32. Protocol No. FE 200486 CS35 06/2009 – 04/2011
Sponsor: Ferring Pharmaceuticals, Inc.
Title: An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy
Role: Sub-Investigator
33. Protocol No. 191622-520 08/2009 – 08/2012
Sponsor: Allergan
Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX[®] (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX[®] as Applicable in Patients with Idiopathic Overactive Bladder with Urinary Incontinence.
Role: Principal Investigator

34. Protocol No. 191622-096 08/2009 – 05/2013
Sponsor: Allergan
Title: Multicenter, Long-term Follow-up Study of the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Idiopathic Overactive Bladder with Urinary Incontinence
Role: Principal Investigator
35. Protocol No. CI-10-0001 02/2010 – 02/2011
Sponsor: Ethicon Endo-Surgery a J & J Company
Title: Pilot clinical trial to study the effectiveness of a four-week exposure to a transcutaneous, high-frequency, amplitude-modulated, non-invasive neurostimulation device on urgency (urinary) incontinence in subjects with idiopathic overactive bladder (OAB)
Role: Principal Investigator
36. Protocol No. 191622-100 07/2010 – 12/2011
Sponsor: Allergan
Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Intraprostatic Administration of BOTOX® 200 U (Botulinum Toxin Type A) Purified Neurotoxin Complex to Treat Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
Role: Principal Investigator
37. Protocol No. AUX-CC-803 07/2010 – 07/2012
Sponsor: Auxilium
Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men with Peyronie's Disease
Role: Sub-Investigator
38. Protocol No. 42160443-PAI-2005 07/2010 – 03/2011
Sponsor: Johnson & Johnson
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects with Interstitial Cystitis/Painful Bladder Syndrome
Role: Sub-Investigator
39. Protocol No. EMK0110 10/2010 – 12/2011
Sponsor: EMKinetics
Title: Magnetic Stimulation of the Posterior Tibial Nerve for Treating Patients with Overactive Bladder (OAB)
Role: Principal Investigator
40. Protocol No. TC BIO-001-0710 09/2011—03/2012
Title: Caris Bio-repository protocol
Prostate Blood Collection
Role: Sub-Investigator

41. Protocol No. EMK0910 11/2011 – 12/2012
Title: EMKinetics
Title: Electrical Field Stimulation for the Treatment of Urge Urinary Incontinence
And Overactive Bladder.
Role: Principal Investigator
42. Protocol No. SPC-SER120-DB3-201101 06/2011 – 12/2014
Sponsor: Serenity Pharmaceuticals
Title: A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter
Study to Investigate the Efficacy and Safety of SER120
Nasal Spray Formulations in Patients with Nocturia.
Role: Principal Investigator
43. Protocol No. TA-501 09/2012 – 06/2013
Sponsor: Vivus
Title: A Randomized, Double-Blind, Placebo Controlled Evaluation of Avanafil for On-
Demand treatment of Men with Erectile Dysfunction.
Role: Sub-Investigator
44. Protocol No. TAR-100-202 03/2013- 03/2015
Sponsor: Taris Biomedical
Title: A Phase 2a Multicenter, Randomized, Double-Blind, Placebo Controlled Study
Evaluating Safety, Tolerability and Efficacy of LIRIS 400 mg in Women With Interstitial
Cystitis Followed by an Open Label Extension.
Role: Principal Investigator
45. Protocol No. STRIVE MDV3100-09 12/2012 – Present
Sponsor: Astellas/Medivation
Title; A Multicenter Phase 2, Randomized, Double-Blind, Efficacy And Safety Study of
Enzalutamide vs Bicalutamide in Men with Prostate Cancer Who Have Failed primary
Androgen Deprivation Therapy.
Role: Sub-Investigator
46. Protocol No. BESIDE 905-EC-012 8/2013-04/2015
Sponsor: Astellas Pharma Europe Limited
Title: A Phase IIIb Study Evaluating the Efficacy and Safety of Mirabegron Plus
Solifenacin compared to Solifenacin
Role: Principal Investigator
47. Protocol No. SPC-SER120-DB4-201301 7/2013-03/2015
Sponsor: Serenity Pharmaceuticals, LLC.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to
Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients with
Nocturia
Role: Principal Investigator

48. Protocol No. ARN-509-003 09/2014-Present
Sponsor: Aragon Pharmaceuticals, LLC.
Title: SPARTAN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Role: Sub-Investigator
49. Protocol No. MDV3100-13 04/2015-Present
Sponsor: Medivation, Inc.
Title: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
Role: Sub-Investigator
50. Protocol No. 178-MA-1005 04/2015-Present
Sponsor: Astellas Scientific & Medical Affairs, Inc.
Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects with Overactive Bladder (OAB)
Role: Principle Investigator
51. Protocol No. 201025-002 06/2015-Present
Sponsor: Allergan
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS 400 mg in Females with Interstitial Cystitis/Bladder Pain Syndrome
Role: Principle Investigator
52. Protocol No. AP311736 06/2015-Present
Sponsor: SFJ Pharma/Pfizer
Title: Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-Blind Phase 3 Study of Adjuvant Axitinib VS. Placebo in Subjects at High Risk of Recurrent RCC
Role: Sub-Investigator

Upcoming research:

1. Saphenous nerve stimulation for the treatment of OAB. Collaboration University of Toronto. Primary investigator. 2016.
2. The GECKO implantable neuromodulation system for OAB. Collaboration with Nuviant Medical. Principle investigator. 2016.
3. Evaluation of a drug delivery balloon dilation catheter for the treatment of urethral stricture disease. Collaboration with Urotronic. Principle investigator. 2016.
4. Evaluation of LiRUS for the treatment of OAB. Co-investigator. 2016.
5. Evaluation of an estrogen receptor agent in the treatment of OAB. Co-investigator. 2016.
6. Evaluation of modified injection technique with onabotulinumtoxinA for the treatment of OAB. CO-investigator.

7. Evaluation of Resiferotoxin for the treatment of OAB and neurogenic detrusor overactivity. 2016.

BIBLIOGRAPHY:

Textbooks:

1. MacDiarmid, S.A., Co-Author: *Urodynamics Made Easy. (2nd edition)* Churchill Livingstone, Publisher, 2000. (*English, French and Chinese Translations)
2. MacDiarmid, S.A., Co-Author: *In Clinical Practice Series: Benign Prostatic Hyperplasia.* Elsevier, Publisher. 2005.
3. MacDiarmid, S.A. Author. *Management of Overactive Bladder.* Remedica, Publisher. 2006.
4. MacDiarmid, S.A., Co-Author. *Urodynamics Made Easy. (3rd edition)* Churchill Livingstone, Publisher. 2008.
5. MacDiarmid, S.A., Co-Author. *Urodynamics Made Easy. (3rd edition)* Churchill Livingstone, Publisher. (French/Spanish/Polish Translations)
6. MacDiarmid, S.A., Co-Editor. *Overactive Bladder. Practical Management.* Wiley-Blackwell. 2015.

Book Chapters:

1. Webster, G.D. and MacDiarmid, S.A.: *Urethral Stricture Disease.* In: Conn's Current Therapy, W. B. Saunders, Philadelphia, 687, 1992.
2. Webster, G.D. and MacDiarmid, S.A.: *Open Urethroplasty, Posterior Urethra.* In: Elder and Horton Text, Reconstructive Surgery of the External Genitalia, Little, Brown, and Co., Boston, 1992.
3. Webster, G.D. and MacDiarmid, S.A.: *Posterior Urethral Stricture Disease.* In: Reconstructive Urology, Webster, Kirby, King, and Goldwasser, Eds. Blackwell Scientific Publishing, Oxford, 2:687, 1992.
4. Webster, G.D. and MacDiarmid, S.A.: *Management of Posterior Urethral Injuries.* In: Urology, Hendry and Kirby, Eds. Churchill Livingstone, 1993.
5. Webster, G.D. and MacDiarmid, S.A.: *Surgical Repair of Urethral Strictures.* In: Contemporary Urology, 5(1):15-20, 1993.
6. MacDiarmid, S.A. and Chapple, C.R.: *Surgical Management of Injuries to the Bladder Neck.* In: Traumatic and Reconstructive Urology, McAninch, Chapter 44, Page 533.
7. MacDiarmid, S.A. and O'Donnell, P.D.: *Pharmacologic Management of Urinary Incontinence in the Elderly.* In: Urinary Incontinence, Mosby-Year Book, Inc., 59:424-429, 1997.
8. MacDiarmid, S.A. and Dept. of Physical Medicine & Rehab, Univ. of Arkansas for Medical Sciences: *Take Control: Multimedia Guide to Spinal Cord Injury.* CD Rom. University of Arkansas for Medical Sciences, Publisher, Volume 1 & 2, 1997.

9. MacDiarmid, S.A. and Leach, G.E.: *Benign Prostatic Hyperplasia: Diagnosis – Need for Urodynamics and Other Testing*. In: Advanced Therapy of Prostatic Disease. B. C. Decker, Inc., Publisher, 1998. (In Press)
10. MacDiarmid, S.A. and Chapple, Chris: *Urinary Incontinence in Females*. In: Urodynamics Made Easy. Churchill Livingstone, Publisher, 2000.
11. MacDiarmid, S.A. and Chapple, Chris: *Post Prostatectomy Incontinence*. In: Urodynamics Made Easy. Churchill Livingstone, Publisher, 2000.
12. MacDiarmid, S.A. and Chapple, Chris: *Simple Urodynamics*. In: Urodynamics Made Easy. Churchill Livingstone, Publisher, 2000.
13. MacDiarmid, S.A. and Chapple, Chris: *Pediatric Urodynamics*. In: Urodynamics Made Easy. Churchill Livingstone, Publisher, 2000.
14. MacDiarmid, S.A. and Chapple, Chris: *Neurogenic Bladder Dysfunction*. In: Urodynamics Made Easy. Churchill Livingstone, Publisher, 2000.
15. MacDiarmid, S.A. *Management of Patients with Neurogenic Bladder*. In: Supportive Care for the Urology Patient. (Norman and Currow). 2005.
16. MacDiarmid, S.A. *Patient Evaluation in Primary Care*. In: In Clinical Practice Series- Benign Prostatic Hyperplasia. Elsevier, Publisher. 2005.
17. MacDiarmid, S.A. *Lower Urinary Tract Symptoms- What is not BPH?* In: In Clinical Practice Series- Benign Prostatic Hyperplasia. Elsevier, Publisher. 2005.
18. MacDiarmid, S.A. *BPH Management Strategies*. In: In Clinical Practice Series- Benign Prostatic Hyperplasia. Elsevier, Publisher. 2005.
19. MacDiarmid, S.A. *Medical Management of BPH*. In: In Clinical Practice Series- Benign Prostatic Hyperplasia. Elsevier, Publisher. 2005.
20. Maximizing the Treatment of OAB with Sacral Nerve Stimulaiton. Overactive Bladder. Practical Management. Wiley-Blackwell. 2014.
21. Percutaneous Tibial Nerve Stimulation: Neuromodulation for the Masses. Practical Functional Urology. Springer. In press. 2015.

Journal Articles

Refereed Journals:

1. MacDiarmid, S.A. and Norman, R.: Extragonadal Non-Seminomatous Germ Cell Tumor with Hyperkalemia Masquerading as Renal Cell Carcinoma. *Urology*, 104:849, 1990.
2. MacDiarmid, S.A. and Norman, R.: 111 Indium-Labelled Leukocytes and 67 Gallium as Indicators of Renal Injury Following Extracorporeal Shock Wave Lithotripsy. *J Urol*, 1990.

3. Awad, S.A., MacDiarmid, S.A., Gajewski, J.B., and Gupta, R.: Idiopathic Reduced Bladder Storage versus Interstitial Cystitis. *J Urol*, 148:1409, 1992.
4. Webster, G.D., MacDiarmid, S.A., Timmons, S.L., et al: Impact of Urinary Diversion Procedures in the Treatment of Interstitial Cystitis and Chronic Bladder Pain. *Neurourol Urodyn*, 11:417, 1992.
5. Perez, L., Barnes, N., MacDiarmid, S.A., and Webster, G.D.: Urologic Dysfunction of Patients with Tethered Cord Secondary to Diastematomyelia: Splitting of the Spinal Cord. *J Urol*, 149:1503, 1993.
6. Wong, K., Thomson, C., MacDiarmid, S.A., Bailey, R.R., and Gardner, J.: Acute Oxalate Nephropathy After a Massive Intravenous Dose of Vitamin C. *Aust NZ J Med*, 24, 1994.
7. Uncommon Complications of Urologic Surgery. *Curr Opin Urol*, Editorial comment, 1994.
8. MacDiarmid, S.A. and Chapple, C.R.: The Importance of Accurate Assessment and Conservative Management of the Open Bladder Neck in Patients with Post-Pelvic Fracture Membranous Urethral Distraction Defect. *Brit J Urol*, 75:65-67, 1995.
9. MacDiarmid, S.A., Arnold, E.P., Anthony, A., and Palmer, N.B.: Management of Spinal Cord Injured Patients by Indwelling Suprapubic Catheterization. *J Urol*, 154:492-494, 1995.
10. Rosario, D.J., Potts, K.L., MacDiarmid, S.A., and Chapple, C.R.: Correlation of Findings on Conventional Urodynamic Studies with Ambulatory Studies in Men with Equivocal Evidence of Bladder Outflow Obstruction. *Neurourol Urodyn*, 14:(5) 529-531, 1995.
11. Post-Prostatectomy Incontinence. *Curr Opin Urol*, Editorial comment, 6:105-110, 1996.
12. Treatment of Intrinsic Sphincter Deficiency. *Curr Opin Urol*, Editorial comment, 6:0-4, 1996.
13. Carr, L.K. and MacDiarmid, S.A.: Management of Complex Anterior Urethral Stricture Disease by Mesh Graft Urethroplasty. *J Urol*, 157:104, 1997.
14. The Pubovaginal Sling. *Curr Opin Urol*, Editorial comment, 7:U1-U4, 1997.
15. Emery, R.T. and MacDiarmid, S.A.: Benign Pelvic Mesothelioma. *Urology*, 50:780, 1997.
16. Folwell, A.J., MacDiarmid, S.A., Crowder, H.J., Lord, A. de M., and Arnold, E.P.: Desmopressin for Nocturnal Enuresis: Urinary Osmolality and Response. *Brit J Urol*, 80:480-484, 1997.
17. MacDiarmid, S.A., Goodson, T.C., Holmes, T.M., Martin, P.R., and Doyle, R.B.: An Assessment of the Comprehension of the American Urological Association Symptom Index. *J Urol*, 159:873, 1998.

18. Transurethral Microwave Thermotherapy and its Role in the Treatment of Benign Prostatic Hyperplasia. *Curr Opin Urol*, 8:U13-U14, 1998.
19. The ABCs of Neurogenic Bladder for the Neurosurgeon. *Contemporary Neurosurgery*, 21(4) 1-8, 1999.
20. Rosario, D.J., MacDiarmid, S.A., Radley, S.C., Chapple, C.R.: A Comparison of Ambulatory and Conventional Urodynamics in Borderline Outflow Obstruction. *BJU Int*, (1999), 83, 400-409.
21. MacDiarmid, S.A., Emery, R.T., Ferguson, S.F., McGuirt-Franklin, R., and Johnson, D.E.: A Randomized Double-Blind Study Assessing 4 Versus 8 mg of Doxazosin in Treating Patients With Benign Prostatic Hyperplasia. *J Urol*, 162: 1629, 1999.
22. MacDiarmid, S.A., Harrigan, C.T., Cottone, J.L., McIntyre, W.J., and Johnson, D.E.: Assessment of a New Transurethral Balloon Dilatation Catheter in the Treatment of Urethral Strictures. *Urology*, Mar;55(3): 408-413, 2000.
23. MacDiarmid, S.A., McIntyre, W.U., Anthony, A., Bailey, R.R., Turner, J.G., and Arnold, E.P.: "Monitoring of Renal Functions in Patients with Spinal Cord Injury." *BJU Int*, (2000), 35, 1-6.
24. Doggweiler, R., Blankenship, J., and MacDiarmid, S.A.: Interstitial Cystitis, The Painful Bladder Syndrome. *Current Review of Pain*, 2000. March 4; 137-141.
25. Doggweiler, R., Blankenship, J., and MacDiarmid, S.A.: Review on Chronic Pelvic Pain From a Urological Point of View. *World Journal of Urology*. Jun3;19(3):160-5, 2001.
26. MacDiarmid, S.A.: *Post-Prostatectomy Incontinence: Pathophysiology and Management*. Current Urology Reports, Current Science 2001;2(3):209-13.
27. Kueter, J. C., MacDiarmid, S. A. and Redman, J.F.: *Anuria Due to Bilateral Ureteral Obstruction by Aspergillus Flavus in an Adult Male*. Urology, Vol. 59: 601vi.-601vii. April, 2002.
28. The Role of Neuromodulation in the Management of Urinary Urge Incontinence. P Abrams, JG Blaivas, CJ Fowler, JL Fourcroy, SA MacDiarmid, SW Siegel, and P Van Kerrebroeck. *BJU International*, 57, 355, 2003.
29. Management of Overactive Bladder and Urinary Incontinence in the Family Practice Setting. *Family Practice Journal* (in press)
30. MacDiarmid, S.A. Antimuscarinic Therapy for the Treatment of Mixed Incontinence. Reviews in Urology, 5(8): 18-25, 2003.
31. MacDiarmid, S.A.: Overactive Bladder. Improving the Efficacy of Anticholinergics by Dose Escalation. Current Urology Reports. 4(6)446-451, 2003.
32. MacDiarmid, S.A. and Whitmore, K.G.: Framework for Understanding Overactive Bladder, Interstitial Cystitis and Urinary Tract Infections. The Female Patient. Supplement 5-8, June, 2003.

33. MacDiarmid, S.A.: Bladder Health Questionnaire. Clinician. The Public Health Implications of Urogenital Disease: A Focus on Overactive Bladder. 22(4):7-8, Sept., 2003.
34. MacDiarmid, S.A.: Living with Interstitial Cystitis. The Female Patient. Supplement 10-14, March, 2004.
35. Doggweiler-Wiygul, R. and MacDiarmid, S.A.: Interstitial Cystitis. The Female Patient: 29:14-22, April, 2004.
36. MacDiarmid, S.A.: Mixed Urinary Incontinence. Effective Evaluation and Treatment. *Contemp Urol*. 17(2): 10-20. 2005.
37. Anderson RU, MacDiarmid SA, et al.: Effectiveness and Tolerability of Extended-Release Oxybutynin vs Extended-Release Tolterodine in Women With or Without Prior Anticholinergic Treatment for Overactive Bladder. *Int Urogynecol Journal*. Nov, 2006.
38. MacDiarmid, S.A.: Outcomes in Incontinence Treatments. The AUA's Topics in Urology Audio Series and CME Enduring Material. Vol. 5. Issue 9. Advancements and New Frontiers in Incontinence and Voiding Dysfunction. 2005.
39. MacDiarmid, S.A.: Mid-urethral Slings and New Procedures and Techniques. The AUA's Topics in Urology Audio Series and CME Enduring Material. Vol. 5. Issue 9. Advancements and New Frontiers in Incontinence and Voiding Dysfunction. 2005.
40. MacDiarmid, S.A. and Dmochowski, R.: Efficacy and Safety of Extended-Release Oxybutynin in the Treatment of Urge Incontinence: An Analysis of Data from Three Flexible-Dosing Studies. *J Urol*. October, 2005.
41. Dmochowski, R., Chen, A., Xiang, J., MacDiarmid, S.A.: Effect of a proton pump inhibitor on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. *J Clin Pharmacol*. 45: 961-968, 2005.
42. MacDiarmid SA and Rosenberg M. Overactive bladder in women: symptom impact and treatment expectations. *Current Medical Research and Opinion*. 21(9): 1413-1421, 2005.
43. Dmochowski R, Sand P, and MacDiarmid SA: Safety and tolerability extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. *Int Urol Nephrol*. Nov, 2006
44. Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, and Guan Zhonghong: Clinical efficacy of tolterodine extended-release is maintained for 24 hours in patients with overactive bladder. *BJU Int*. 100: 107-110. 2007.
45. MacDiarmid SA and Sand PK: Diagnosis of interstitial cystitis/painful bladder syndrome in patients with overactive bladder symptoms. *Reviews in Urology*. 8(4): 9-16, 2006.
46. Staskin DR and MacDiarmid SA.: Using Anticholinergics to Treat Overactive Bladder: The Issue of Treatment Tolerability. *Amer J Med*. 119(3A): 9S-15S, 2006.
47. Staskin DR and MacDiarmid SA: Pharmacologic Management of Overactive Bladder: Practical Options for the Primary Care Physician. *Amer J Med* 119(3A): 24S-28S. 2006.

48. Diokno A, Sand P, MacDiarmid SA, et al.: Perceptions and behavior of women with bladder control problems. *Family Practice*. 23: 568-577, 2006.
49. Hodges D and MacDiarmid SA.: Congenital Urethroperineal Fistula. *Applied Radiology. Radiological Case of the Month*. 2006.
50. MacDiarmid SA and Rosenberg. Overactive bladder in women: symptom impact and treatment expectations. *Current Medical Research and Opinions*. 21: 1413-1421, 2005.
51. MacDiarmid SA, et al.: Management of incontinence for family practice physicians. *AJM supplement*. 2005.
52. MacDiarmid SA.: Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? *BJU Int*. 99(suppl 3): 8-12, 2007.
53. MacDiarmid SA and Rogers A.: Male Overactive Bladder: The Role of Urodynamics and Anticholinergics. *Current Urology Reports*. 8: 66-73. 2007.
54. MacDiarmid SA: Combination Antimuscarinics and Apha-Blockers for Benign Prostatic Hyperplasia. *Current Prostate Reports*. (5) 2: 71-77, 2008.
55. Rosenberg MT, Staskin DR, Kaplan SA, MacDiarmid SA, et al.: A Practical Guide to the Evaluation and Treatment of Male Lower Urinary Tract Symptoms in the Primary Care Setting. *Int J Clin Pract*. 61(9): 1535-1546. Sept, 2007.
56. MacDiarmid SA: Concomitant Medications and Possible Side Effects of Antimuscarinic Agents. *Review in Urology*. 10(2): 92-98, 2008.
57. MacDiarmid SA: How to Choose the Initial Drug Treatment for Overactive Bladder. *Current Bladder Dysfunction Reports*. 3: 41-46, 2008. (located on UroToday.com)
58. MacDiarmid SA: Maximizing the Treatment of Overactive Bladder in the Elderly. *Reviews in Urology*. 10(1) 6-13, 2008.
59. MacDiarmid SA: Better Management of Patients with Overactive Bladder with Antimuscarinics. (editorial comment) *Int J Clin Pract*. 62: 3-4, 2008.
60. MacDiarmid SA, Sandage BW and Malhotra BK.: The Effects of Reformulation: Improved Therapeutic Index. *Current Urology Reports*. (9) 6; 465-471, Nov, 2008.
61. MacDiarmid SA: Combination Antimuscarinics and Apha-Blockers for Benign Prostatic Hyperplasia. *Current Urology Reports*. (9) 4:265-271, 2008.
62. MacDiarmid SA, Peters KM, Chen A, et al.: Efficacy and Safety of Extended-Release Oxybutynin in Combination with Tamsulosin for Treatment of Lower Urinary Tract Symptoms in Men: Randomized, Double-Blind, Placebo-Controlled Study. *Mayo Clin Proc*. 83(9): 1002-1010, 2008.
63. MacDiarmid SA. The Evolution of Transdermal/Topical Overactive Bladder Therapy and Its Benefits Over Oral Therapy. *Rev Urol*. 11: 1-6. 2009.

64. MacDiarmid SA and Staskin DR. Percutaneous Tibial Nerve Stimulation (PTNS): A Literature-Based Assessment. *Curr Bladder Dysfx Reports*. 4: 29-33. 2010.
65. Hershorn S, Jones JS, MacDiarmid SA, et al.: Efficacy and Tolerability of Fesoterodine in Men with Overactive Bladder: A Pooled Analysis of 2 Phase III Studies. *Urology*. 75(5): 1149-55. 2010.
66. Peters KM, MacDiarmid SA, Wooldridge LS, et al.: Randomized Trial of Percutaneous Tibial Nerve Stimulation versus Extended-Release Tolterodine: Results from the Overactive Bladder Innovative Therapy Trial. *J Urol*. 182(3): 1055-61. 2010.
67. MacDiarmid SA, Peters KM, Shobeiri SA, et al.: Long-Term Durability of Percutaneous Tibial Nerve Stimulation for Overactive Bladder. *Beyond the Abstract*. UroToday. 2010.
68. Malhortra BM, Crownover PH, MacDiarmid SA. et al.: The Pharmacological Profile of Fesoterodine 8 mg With Daytime or Nighttime Dosing. *Eur J Clin Pharmacol*. 66: 171-176. 2010.
69. MacDiarmid SA. Peters KM, Shobeiri SA. et al.: Long-Term Durability of Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder. *J Urol*. 183. 234-240. 2010.
70. MacDiarmid SA, Hill LA, Volinn W. et al.: Lack of Pharmacodynamic Interaction of Silodosin, a Highly Selective Alpha 1a-adrenoceptor Antagonist, With the Phosphodiesterase-5 Inhibitors Sildenafil and Tadalafil in Healthy Men. *Urology*. 75(3): 520-525. 2010.
71. Hershorn S, Jones SJ, Oelke M, MacDiarmid SA, et al.: Efficacy and Tolerability of Fesoterodine in Men with Overactive Bladder: A Pooled Analysis of 2 Phase III Studies. *Urology*. 75(5): 1149-1155. 2010.
72. MacDiarmid SA, Ellsworth PI, Ginsberg DA, et al.: Safety and Efficacy of Once-Daily Trospium Chloride Extended-Release in Male Patients With Overactive Bladder. *Urology*. Oct, 2010.
73. Peters KM, Corrico D, MacDiarmid SA. et al.: Randomized Trial of Percutaneous Tibial Nerve Stimulation versus Sham in the Treatment of Overactive Bladder Syndrome: Results of the SUmIT Trial. *J Urol*. 183: 1438-43. 2010.
74. Lukacz ES, Sampselle C, MacDiarmid SA. et al.: A Healthy Bladder: A Consensus Statement. *Int J Clin Pract*. 65(10): 1026-36. 2011.
75. Staskin DR, Peters KM, MacDiarmid SA. et al.: Percutaneous Tibial Nerve Stimulation: A Clinically and Cost Effective Addition to the Overactive Bladder Algorithm of Care. *Curr Urol Rep*. 13(5): 327-334. 2012.
76. Sand PK, MacDiarmid SA, et al. Effect of Baseline Symptom Severity on Continence Improvement Mediated by Oxybutynin Chloride Topical Gel. *Research and Reports Urol*. 2011 (3). 145-150. 2012.

77. Kay GG, Staskin DR, MacDiarmid SA. et al.: Cognitive effects of oxybutynin chloride topical gel in older subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study. *Clinical Drug Investigation*. 32(10): 707-714. 2012.
78. Burks J, Chancellor M, MacDiarmid SA, et al.: Development and Validation of the Actionable Bladder Symptom Screening Tool in MS Patients. *IJMISC*. 15(4): 182-92. 2013.
79. Bates D, Burks J, MacDiarmid SA, et al.: Development of a Short Form and Scoring Algorithm form the Validated Actionable Bladder Symptom Screening Tool. *BMC Neurology*. 13: 1-13.
80. Martinson M, MacDiarmid SA, Black E. Cost of Neuromodulation Therapies for Overactive Bladder: Percutaneous Tibial Nerve Stimulation Versus Sacral Nerve Stimulation. *J Urol*. 189: 210-216. 2013.
81. Peters KM, Carrico DJ, MacDiarmid SA, at al.: Sustained Therapeutic Effects of Percutaneous Tibial Nerve Stimulation: A 24-Month Results of the STEP Study. *Neuro Urol. Urodyn*. 32(1): 24-29. 2013.
82. Peters KM, Carrico DJ, MacDiarmid SA. et al.: Percutaneous Tibial Nerve Stimualtion for the Long-Term Treatment of Overactive Bladder: 3-year Results of the STEP Study. *J Urol*. 189: 2194-2201. 2013.
83. Chapple C, Siervert K-D, MacDiarmid SA, et al.: OnabotulinumtoxinA 100U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomized, Double-Blind, Placebo-Controlled Trial. *Eur Assoc Urol*. 64: 249-256. 2013.
84. Whydaele JJ, Schneider T, MacDiarmid SA, et al.: Flexible Dosing with Fesoterodine 4 and 8 mg: A Systematic Review of Data from Clinical Trials. *Int J Clin Pract*. 1-11, 2014.
85. MacDiarmid SA. Posterior Tibial Nerve Stimulation Before a Trial of Sacral Nerve Stimulation for Refractory Overactive Bladder. *Opposing Views. J Urol*. 191: 1-3. 2014.
86. Cardozo L, Staskin DR, MacDiarmid SA. et. al.: Validation of a Bladder Symptom Screening Tool with Incontinence due to Overactive Bladder. *Internat Urogynecol J*. 25(12): 1655-63. 2014.

Non-Refereed Journals:

1. *Solutions for Post-Prostatectomy Incontinence*. Colleagues in Urology, Editorial comment, 1995.
2. *The Role of the Incontinence Nurse Specialist in the Treatment of Urinary Incontinence*. Colleagues in Urology, Editorial comment, 1995.
3. *Physicians Enthusiastic About AMS Malleable 650 Prosthesis*. Colleagues in Urology, Editorial comment, 1996.

4. *The Balance Between Marketing and Advertising*. Colleagues in Urology, Editorial comment, 1997.
5. *Management of Urethral Strictures*. Education Supplement, Microvasive, June, 1998.
6. *Alpha Blockade and the Theory of Uroselectivity in the Treatment of BPH (Medi fax)*. University of Florida Express Report from data presented at the American Urological Association 93rd Annual Meeting, July, 1998.
7. MacDiarmid, S.A., Granville, L., Voluck, R., Lipsky, M., Newman, D., and Woodman, P.: *A Primary Care Provider's Search for an Approach to Bladder Control Problems*. Veterans Health System Journal. Vol.5. No.5. June 2000.
8. MacDiarmid, S.A., et al.: *The Pharmacologic Treatment of Overactive Bladder Pocket Card Reference*. Veterans Health System Journal. Vol.5. No.5. June 2000.
9. Healthy Mom- I Gotta Go! H Gowen, SA MacDiarmid. Parents Magazine. September, 2002.
10. The Hidden Health Problem That Women Don't Talk About: Overactive Bladder R Rabkin, SA MacDiarmid. Family Circle Magazine, April, 2003.
11. MacDiarmid, S.A.: Insights Into Managing Overactive Bladder. Therapeutic Bulletin Reports. Pg. 1-4. May, 2003.
12. Framework for Understanding Bladder Health Conditions: Overactive Bladder, Interstitial Cystitis, Urinary Tract Infection. SA MacDiarmid, K Whitmore. The Female Patient Supplement, July, 2003.
13. MacDiarmid, S.A.: *Pelvic Floor Muscles (Kegel) Exercises*. Parents Magazine. H. Gowen, SA MacDiarmid.
14. MacDiarmid, S.A.: Improving Efficacy of Anticholinergics by Dose Escalation. AUA News. May, 2004.
15. MacDiarmid, S.A.: Overactive Bladder: An Embarrassing Medical Condition is Treatable. Patient Education Supplement. 2004.
16. MacDiarmid, S.A.: Overactive Bladder: The Primary Care Provider's View.
17. MacDiarmid, S.A.: Overactive Bladder article. Self Magazine. April, 2005.
18. MacDiarmid, S.A.: The Clinical Management of Patients with OAB Can Be Improved with Transdermal Drug Delivery. Special Report on Overactive Bladder. The Chronicle of Urology and Sexual Medicine. June, 2005.
19. MacDiarmid, S.A.: Bladder Matters: Overactive Bladder and Interstitial Cystitis. CD Rom. Faculty Presentation Kit. 2005.
20. MacDiarmid, SA: Myths and Facts of OAB Brochure (YAM05-1920). Disease Awareness of Overactive Bladder. Primary Care Supplement. Adis data information, 2005.

21. MacDiarmid, SA: Improving Outcomes with Extended-Release Oxybutynin Through Flexible Dosing. www.reutershealth.com. 2005.
22. MacDiamrid, SA: Women's Health- Potty Parity Could Lead to Shorter Lines But Some Women It's Not Enough. DXLPottyParityMAT. Jan, 2006.
23. MacDiarmid, S.A. and Rosenberg MT: The Drive for Dryness in OAB: Primary Care Approaches to Improving Quality of Life. Pri-Med in Practice. 4(3), 10-11, 2006.
24. MacDiarmid, SA et al.: Optimizing Outcomes by Integrating Clinical Trial Data into Clinical Practice. Medical Crossfire: Overactive Bladder. Supplement, 2006.
25. MacDiarmid, SA: Therapeutic Management of Overactive Bladder- A CME/CE Initiative. Veritas Institute for Medical Education Newsletter. May, 2006.
26. MacDiarmid, SA: Antimuscarinic Therapy in Male Patients with Overactive Bladder. US Genito-Urinary Disease. 2006.
27. MacDiarmid, SA: An Update for Managed Care: Pharmacologic Management of Overactive Bladder. 2006.
28. MacDiarmid, SA: The Urge to Define Urgency. Expert Opinions on Urgency Study Design and Outcomes in OAB. Urology Times. Oct, 2007.
29. MacDiarmid, SA: Managing Urinary Incontinence in Women. Guidelines Pocketcard. Version 1.0. 2006.
30. MacDiarmid, SA: The Management of Overactive Bladder in the Primary Care Setting. Primary Care Network Primary Issues Newsletter. p. 18-27, 2008.
31. MacDiarmid, SA: BPH for Primary Care Physicians: A Practical Guide for the Primary Care Physician. Primary Care Network Primary Issues Newsletter. (10) 4: 18-25, 2008.
32. MacDiarmid, SA: Diagnosing and Treating Male LUTS in the Primary Care Setting: A Case Series. www.medscape.com/case/luts. 2008. (CME/CE)
33. MacDiarmid, SA: OAB Spotlight: Focus on Flexible Dosing. CME Spotlight-Epocrates. 2008.
34. MacDiarmid SA, et al.: Emerging Therapies for Prostate Cancer, Benign Prostatic Hyperplasia, and Overactive Bladder. Industry Clinical Update Newsletter. Watson. MedReviews. 2010.
35. MacDiarmid, SA., et. al.: Safety and Efficacy of Once-Daily Trosipium Chloride Extended-Release in Male Patients with OAB. Ambulatory and Office Urology. Abstract UroToday.com. Oct, 2010.
36. MacDiarmid, SA: Urgent PC for OAB. EmpowerER e-bulletin March, 2012.
37. MacDiarmid, SA: Neurostimulation Treatment for OAB: An Evaluation of Cost Effectiveness Data – Session Highlights of SUFU Winter Meeting, 2013. URO TODAY e-bulletin.

38. MacDiarmid, SA: Myrberiq: Efficacy Data. Astellas Rx peer insights supplement. May, 2014.
39. MacDiarmid. Maximizing Anticholinergic Therapy for OAB. Pubmed Advanced. March, 2015.
40. MacDiarmid, SA (co-author): Neuromodulation. The Percutaneous Approach: Past, Present and Future. Urology Times. June, 2014.
41. MacDiarmid, SA: PTNS for Overactive Bladder: Patient Selection and Technique. Urology Times Hands On. P. 12-14. February, 2015.

ACADEMIC PRESENTATIONS:

1. *Renal Scan Post-ESWL*, Canadian Urologic Association, Quebec, Canada, 1989.
2. *Interstitial Cystitis and Reduced Bladder Storage in Women with Mixed Stress and Urge Incontinence*, Canadian Urologic Association, Vancouver, Canada, 1990.
3. *Interstitial Cystitis and Reduced Bladder Storage in Women with Mixed Stress and Urge Incontinence*, Northeastern Section of the American Urological Association, Halifax, Canada, 1990.
4. *Interstitial Cystitis and Reduced Bladder Storage in Women with Mixed Stress and Urge Incontinence*, American Urological Association, New Orleans, LA, 1990.
5. *Urologic Dysfunction of Patients with Tethered Cord Secondary to Diastematomyelia: Splitting of the Spinal Cord*, Southeastern Section of the American Urological Association, Charlotte, NC, 1992.
6. *Complex Urethral Stricture Disease*, Teton Urologic Association, Jackson Hole, WY, 1992.
7. Faculty Speaker. Society for Urodynamics and Female Urology (SUFU). "Debate-Virgin Stress Urinary Incontinence: Pubovaginal Sling vs. TVT/SPARC." American Urological Association Annual Meeting. May, 1992.
8. *Mesh Graft Urethroplasty in Complex Urethral Stricture Disease*, Southeastern Section of the American Urological Association, Charlotte, North Carolina, 1992.
9. Urologic Dysfunction of Patients with Tethered Cord Secondary to Diastematomyelia: Splitting of the Spinal Cord, American Urological Association, Washington, D.C. (Poster), 1992. Urinary Diversion in Patients with Interstitial Cystitis, International Continence Society, Halifax, Canada, 1993.
10. Urinary Diversion in Patients with Interstitial Cystitis, International Continence Society, Halifax, Canada, 1993.
11. Factors Associated with Bowel Dysfunction Following Cystoplasty, American Urological Association, San Antonio (Poster), 1993.

12. Long-Term Management of Spinal Cord Injured Patients by Suprapubic Catheterization, European Urological Association, Berlin, Germany, 1994.
13. Long-Term Management of Spinal Cord Injured Patients by Suprapubic Catheterization, The British Association of Urologic Surgeons, Birmingham, England (Poster), 1994.
14. Alternative Forms of Bladder Management in Patients with Spinal Cord Injury, South Central Section of the American Urological Association, Vancouver, Canada, 1994.
15. *Long-Term Management of Spinal Cord Injured Patients by Suprapubic Catheterization*, American Urological Association, San Francisco, California, 1994.
16. *Urinary Diversion in Patients with Interstitial Cystitis*, South Central Section of the American Urological Association, Vancouver, British Columbia, Canada, 1994.
17. *Correlation of Findings of Conventional Urodynamic Studies with Ambulatory Studies in Men with Equivocal Evidence of Bladder Outflow Obstruction*, International Continence Society, Sydney, Australia, 1995.
18. Ambulatory Urodynamics in Patients with Benign Prostatic Hyperplasia, The British Association of Urologic Surgeons, England, 1995.
19. *Assessment of Renal Function in Spinal Cord Injured Patients*, South Central Section of the American Urological Association, Kansas City, KS (Poster), 1995.
20. *A Comparison of Ambulatory and Conventional Pressure-Flow Urodynamics*, South Central Section of the American Urological Association, Kansas City, KS, 1995.
21. *Individualized Dosing of Extended-Release Oxybutynin is Associated with Improved Outcomes in the Treatment of Urge Incontinence*. 26th Annual AUGS Scientific Meeting, May, 2005.
22. *The Impact of Obstructive vs. Irritative Urinary Symptoms on Quality of Life (QOL): Extending the Clinical Usefulness of the American Urological Association (AUA) Index*, American Urological Association, Orlando, FL, 1996.
23. *Management of Complex Anterior Urethral Stricture Disease by Mesh Graft Urethroplasty*, American Urological Association, Orlando, FL (Poster), 1996.
24. Does Bladder Defunctionalization Alter Cystometry in Patients with Post-Prostatectomy Incontinence, South Central Section of the American Urological Association, Vail, CO, 1996.
25. The Impact of Obstructive vs. Irritative Urinary Symptoms on Quality of Life (QOL): Extending the Clinical Usefulness of the American Urological Association (AUA) Index, South Central Section of the American Urological Association, Vail, CO, 1996.
26. *The American Urological Association (AUA) Symptom Index: Can Patients Read and Understand It?*, South Central Section of the American Urological Association, Vail, CO, 1996.

27. A Preliminary Assessment of a New Transurethral Balloon Dilatation Catheter in the Treatment of Urethral Stricture Disease, South Central Section Meeting, American Urological Association, Bermuda, (Podium), November, 1997.
28. *The Accuracy of the BVI 2500 Bladder scan in the Measurement of Residual Urine Volume in Pediatric Patients*, South Central Section Meeting, American Urological Association, Bermuda, (Podium), November, 1997.
29. *Urodynamic Assessment of Bladder Function Before and After Radical Prostatectomy*, South Central Section Meeting, American Urological Association, Bermuda, (Podium), November, 1997.
30. *Treatment of Post Radical Prostatectomy Bladder Neck Contractures With a New Transurethral Balloon Dilatation Catheter*, South Central Section Meeting, American Urological Association, Cancun, Mexico, (Podium), November, 1998. Essay Finalist.
31. *Assessment of a New Transurethral Balloon Dilatation Catheter in the Treatment of Urethral Stricture Disease*, South Central Section Meeting, American Urological Association, Cancun, Mexico, (Podium), 1998.
32. *Detrusor Hyperactivity in Patients Following Radical Prostatectomy: An Acquired or Persistent Urodynamic Abnormality?*, South Central Section Meeting, American Urological Association, Cancun, Mexico, (Podium), 1998.
32. *The Abdominal Complications Associated With the Rectus Pubovaginal Sling Cystourethropexy*, South Central Section Meeting, American Urological Association, Cancun, Mexico, (Podium), 1998.
33. *A Randomized Double-Blind Study Assessing the Optimal Dosage of Doxazosin in Treating Patients With Benign Prostatic Hyperplasia*, South Central Section Meeting, American Urological Association, Cancun, Mexico, (Podium), 1998.
34. *A Randomized Double-Blind Study Assessing the Optimal Dosage of Doxazosin in Treating Patients With Benign Prostatic Hyperplasia*, American Urological Association Meeting, San Diego, CA, (Poster), 1998.
35. *Assessment of a New Transurethral Balloon Dilatation Catheter in the Treatment of Urethral Stricture Disease*, 16th World Congress of Endourology and SWL, New York, NY, (Poster), 1998.
36. *Treatment of Post-Radical Prostatectomy Bladder Neck Contractures With a New Transurethral Balloon Dilatation Catheter*, 16th World Congress of Endourology and SWL, New York, NY, (Poster), 1998. **Award – Best Poster.**
37. *Detrusor Hyperactivity in Patients Following Radical Prostatectomy: An Acquired or Persistent Urodynamic Abnormality?*, American Urological Association Meeting, Dallas, TX, (Poster), 1999.
38. *Detrusor Hyperactivity in Patients Following Radical Prostatectomy: An Acquired or Persistent Urodynamic Abnormality?*, Society for Urodynamics and Female Urology, American Urological Association Meeting, Dallas, TX, (Poster), 1999. (One of ten posters chosen for oral presentation.)

39. *Interstitial Laser Coagulation of the Prostate —A Pressure-Flow Analysis*. American Urological Association Meeting, Atlanta, GA, 2000 (Poster).
40. *Interstitial Laser Coagulation of Prostate – A Pressure-Flow Analysis*. South Central Section Meeting, American Urological Association, Montreal, Canada, (Podium), 2000.
41. *Medical Management of Female Patients With Mixed Stress/Urge Incontinence*. South Central Section Meeting, American Urological Association, Montreal, Canada, (Podium), 2000.
42. *Virgin Stress Urinary Incontinence: PV Sling vs.TVT/SPARC*. Society for Urodynamics and Female Urology (SUFU). American Urological Association Meeting. Orlando, FL, 2002.
43. *Management of Generator Site Pain With a Lidoderm 5% Patch in Pelvic Pain Patients Treated With Sacral Nerve Stimulation*. International Continence Society Meeting. Heidelberg, Germany, 2002.
44. *Efficacy of Sacral Nerve Stimulation in Combination With Behavioral and Physical Therapy in the Treatment of Pelvic Pain and Voiding Dysfunction*. R. Wiygul, SA MacDiarmid, S Rueff. American Urological Association Annual Meeting, Chicago, May, 2003.
45. *Urodynamic Parameters Correlate With Clinical Outcome Measures of Frequency of Micturitions and Incontinent Episodes*. BW Sandage, M Harnett, SA MacDiarmid, A Wiedemann, G Primus, K Hofner. International Continence Society 33rd Annual Meeting. Florence, Italy, October, 2003.
46. *Dual Botulinum Toxin Injection Therapy in the Treatment of Dysfunctional Voiding and Pelvic Pain Syndrome*. R. Wiygul, SA MacDiarmid, S Rueff. International Continence Society 33rd Annual Meeting. Florence, Italy, 2003.
47. *Management of Overactive Bladder and Urinary Incontinence in the Family Practice Setting*. SA MacDiarmid, M. Rosenberg. American Academy of Family Practitioners Annual Meeting. October, 2003.
48. *Effect of a Proton Pump Inhibitor on the Pharmacokinetics of Extended-Release Oxybutynin and Tolterodine*. American Urological Association Meeting. San Francisco. 2004 (Poster)
49. *Are Differences in Delivery Systems, Pharmacokinetics, and Metabolism Clinically Relevant?* AUA Course. American Urological Association Meeting. San Francisco. 2004.
50. *Maximizing the Treatment of Overactive Bladder: “Tricks of the Trade.”* AUA Course. American Urological Association Meeting. San Francisco. 2004.
51. *Outcome Measures for Assessing Efficacy of Incontinence Procedures*. AUA Post-Graduate Course. American Urological Association Meeting. San Francisco. 2004.
52. *Mid-urethral Slings*. AUA Post-Graduate Course. American Urological Association

Meeting. San Francisco. 2004.

53. *Urinary Incontinence and Incident Disability in Community-Dwelling Older Women.* Joint Annual Meeting of the Society for Urodynamics and Female Urology and the International Society of Pelvic Neuromodulation. Orlando, Florida. February, 2005. **"Highlight Abstract Selected for Publication"**
54. *Flexible Dosing of Extended-Release Oxybutynin Improves Treatment Outcomes for Urge Incontinence.* The 53rd Annual Clinical Meeting of the American College of Obstetricians and Gynecologists. San Francisco. May, 2005. **"Blue Ribbon Prize Winner"**
55. *Urinary Incontinence and Incident Disability in Community-Dwelling Older Women.* American Urological Association Annual Meeting. San Antonio, Texas. May, 2005. (moderated poster)
56. *Conservative Management for Urethral Stricture Disease.* Society of Genitourinary Reconstructive Surgeons. American Urological Association Annual Meeting. San Antonio. May, 2005.
57. *The Distribution of Oxybutynin Chloride and Tolterodine Tartrate in Mice.* Southeastern Section AUA Annual Meeting. 2005.
57. *Mid-urethral Slings and Pelvic Organ Prolapse.* Post-Graduate Course. American Urological Association Annual Meeting. San Antonio. May, 2005.
58. *Comparing the Impact of Transdermal Oxybutynin on nocturia and related symptoms in men and women with overactive bladder: results from the MATRIX study.* Society for Urodynamics and Female Urology Winter Meeting. Feb, 2006.
59. *Tamsulosin and Extended-Release Oxybutynin: Effects of Combination Therapy on Lower Urinary Tract Symptoms in Men.* New England Sectional AUA. Sept, 2006. (poster presentation)
60. *Effects of Tamsulosin and Extended-Release Oxybutynin on Lower Urinary Tract Symptoms in Men.* American Urologic Annual Meeting. Atlanta, GA. 2005
61. *Differences in Impact of Overactive Bladder on Quality of Life Between Men and Women: Interim Results From the Matrix Study.* International Continence Society Annual Meeting, Montreal, Canada. Sept, 2005.
62. *Individualized Dosing of Extended-Release Oxybutynin is Associated with Improved Outcomes the Treatment of Urge Incontinence.* American Urogynecologic Society Scientific Meeting, Sept, 2005. (Poster presentation)
63. *Effect of a Fixed Dose Extended-Release Oxybutynin on Urge and Non-Urge Urinary Incontinence.* Society for Urodynamics and Female Urology Winter Meeting, Bahamas. Feb, 2006.
64. *Effects of Tamsulosin and Extended-Release Oxybutynin on Storage symptoms in Men Aged 65 Years and Over.* American Geriatric Society Annual Meeting. Chicago. May, 2006.

65. *Dry Rates with Trosipium Chloride 60 Mg Once Daily are Significantly Superior to Placebo*. Northeastern Section AUA Annual Meeting. Sept, 2007. (Poster)
66. *Management of Tegress Erosion into the Urethra*. South Central Section AUA Annual Meeting. 2007.
67. *Elevated Postvoid Residual Urine Volume in Men with OAB at High Risk of Urinary Retention*. South Central Section AUA Annual Meeting. 2007.
68. *Elevated Postvoid Residual Urine Volume in Men with OAB at High Risk of Urinary Retention*. Society for Urodynamics and Female Urology Winter Meeting, Feb, 2007. (***resident best paper award**)
69. *Transvaginal Repair of Neobladder-Vaginal Fistula Using Martius Flap*. Society for Urodynamics and Female Urology Annual Meeting. 2007.
70. *A Randomized Multicenter Study Comparing Percutaneous Tibial Nerve Stimulation with Pharmaceutical Therapy for the Treatment of Overactive Bladder*. AUA Annual Meeting. Orlando, FL. May, 2008. (***accepted in 2008 Late Breaking Science Forum**)
71. *Pharmacodynamic Interaction of Silodosin, a Highly Uroselective Alpha-Blocker With the Phosphodiesterase-5 Inhibitors Sildenafil and Tadalafil in Healthy Men*. Sexual Medicine Society of North America Annual Meeting. Toronto, Canada. Oct, 2008.
72. *Phase III Efficacy of Oxybutynin Gel in the Treatment of OAB*. AUA Annual Meeting. Podium presentation. Chicago, IL. 2009.
73. *The Long-Term Therapeutic Effect of Percutaneous Tibial Nerve Stimulation in the Management of OAB*. AUA Annual Meeting. Moderated poster. Chicago, IL 2009.
74. *Female Urology: Controversies and Consensus – A Case Based Approach. Maximizing Efficacy of Oral Agents*. AUA Annual Meeting. Review Course. Chicago, IL. 2009.
75. *A Randomized Multicenter Study Comparing Percutaneous Tibial Nerve Stimulation with Pharmaceutical Therapy for the Treatment of OAB*. Moderated poster. AUA Annual Meeting. Chicago, IL, 2009.
76. *Are the effects of oxybutynin on cognition dependent upon route of administration – topical or oral agent? A double-blind placebo controlled study employing sensitive cognitive and psychomotor testing*. International Continence Society Annual Meeting. Moderated Poster. San Francisco, California. 2009.
77. *AUA Clinical Theatre Update. A Scientific Debate on Parameters Used in Measuring Efficacy, Safety, and Tolerability*. AUA Annual Meeting. Chicago, IL. 2009.
78. *The Safety of Once-Daily Extended Release Antimuscarinic Therapy in Men with OAB*. Western AUA Annual Meeting. Unmoderated poster. 2009.
79. *Academics vs. Private Practice: what is the Best Choice for Me? The Gerald P. Murphy Luncheon*. AUA Annual Meeting. Chicago, IL, 2009.

80. Percutaneous Tibial Nerve Stimulation and Effect on Fecal Incontinence. The Results from Two Recent OAB Trials. American Society of ColonRectal Surgeons Annual Meeting. Minneapolis, MN. 2010.
81. The Safety of Once-Daily Extended-Release Antimuscarinic Therapy in Men with OAB. Society of Urodynamics and Female Urology Annual Meeting. St Petersburg, FL. 2010.
82. 12 Month Percutaneous Tibial nerve Stimulation Treatment Interval Results: Outcomes From the ORBIT Trial. ICS/IUGA Annual Meeting. Toronto, Ontario. 2010.
83. Individualized Approach: The Clinical Value of Toviaz 4 and 8 mg. ICS/IUGA Annual Meeting. Toronto, Ontario. 2010.
84. The Effect of Severity of Incontinence on the Efficacy of Oxybutynin Chloride Topical Gel in Improving Continence. New England 79th AUA Annual Meeting. 2010.
85. OAB Therapy SUFU Symposium. Society of Urodynamics and Female Urology Annual Meeting. St Petersburg, FL. 2010.
86. Taking Control: Targeting LUTS in BPH. South Central Section AUA Annual Meeting. White Sulphur Springs, WV. 2010.
87. Percutaneous Tibial Nerve Stimulation: a Multi-center, Randomized, Sham-controlled trial for OAB. Podium presentation. AUA Annual Meeting. San Francisco, CA. 2010.
88. The Effect of Severity of Incontinence on the Efficacy of Oxybutynin Chloride Topical Gel in Improving Continence. Mid-Atlantic AUA Annual Meeting. Farmington, PA. 2010.
89. A Directed Open Forum on Current Topics in Neuromodulation. Percutaneous Tibial Nerve Stimulation. Society of Female Urology and Urodynamics Annual Meeting. Scottsdale, Arizona. 2010.
90. No effect of Incontinence on the Efficacy of Oxybutynin Topical Gel in Improving Continence. Southeastern Section AUA Annual Meeting. Austin, TX. 2010.
91. The Effects of Topical and Oral Oxybutynin on Cognitive and Psychomotor Functions in Older Adults- A double-Blind, Placebo-Controlled Study. Southeastern Section Annual Meeting. New Orleans, LA. 2011.
92. Critical Analysis of Fesoterodine in the Treatment of OAB. ACOG District II Annual Meeting. New York, NY. 2011.
93. Critical Analysis of Fesoterodine in the Treatment of OAB. AUA Mid Atlantic New England Annual Meeting. Orlando, FL. 2011.
94. Posterior Tibial Nerve Stimulation. Hands-on Neuromodulation Review Course. Beaumont Hospital. Dearborn, Michigan. 2011.
95. The Effects of Topical and Oral Oxybutynin on Cognitive and Psychomotor Functions in Older Adults- A double-Blind, Placebo-Controlled Study. Moderated Poster. North Central Section Annual Meeting. Chicago, IL. 2011.

96. Does Symptom Severity Affect Oxybutynin Topical Gel – Mediated Improvement of Continence in Women? Poster presentation. American College of Obstetricians and Gynecologists Annual Meeting. Washington, DC. 2011.
97. Treatment Interval Frequency of PTNS: Preliminary Results from the STEP Study. AUA Annual Meeting, 2011. Washington, DC. 2011.
98. Development and Validation of Urinary Incontinence in Multiple Sclerosis Tool. Moderated Poster. International Continence Society. Glasgow, Scotland. 2011.
99. Insight into PTNS: Critical Evaluation of the SUMIT Trial. Moderated Poster. AUA Annual Meeting, 2011. Washington, DC. 2011.
100. Health-related Quality of Life in Patients with OAB. Podium presentation. 27th Congress of European Association of Urology. Paris, France. 2012.
101. Neuromodulation Treatment for OAB: An Evaluation of Cost Effectiveness. AUA/Japan Annual Meeting. BEST POSTER. Tokyo, Japan. 2012.
102. A Novel, Patient-Managed Neuromodulation System (PMNS) Using a Patch for Treatment of OAB with Urgency Urinary Incontinence. Moderated poster. BEST POSTER. 27th Congress of European Association of Urology. Paris, France. 2012.
103. Individualizing Care for Patients with OAB. Southeastern Section of AUA Annual Meeting. Amelia Island, FL. 2012.
104. Botulinum Toxin for the Treatment of Neurogenic Detrusor Overactivity. Puerto Rico Urological Annual Meeting. San Juan, Puerto Rico. 2012.
105. Urodynamics: When, Why... Or Why Not? Puerto Rico Urological Annual Meeting. San Juan, Puerto Rico. 2012.
106. Neuromodulation: PTNS and SNS. Mid Atlantic Section of AUA Annual Meeting. Philadelphia, PA. 2012.
107. Pivotal Phase III Study in OAB Patients with Urinary Incontinence Confirms OnabotulinumtoxinA 100U Significantly Improves OAB Symptoms and Patients' Quality of Life. Poster presentation. 28th Congress of European Association of Urology. Milan, Italy, 2013.
108. Development and Validation of Urinary Incontinence in Multiple Sclerosis Tool. Moderated Poster. Nonmoderated poster. IUGA. 2013.
109. Validation of the Actionable Bladder Symptoms Screening Tool (ABSST) in Males and Females with OAB and Urinary Urgency Incontinence. 28th Congress of European Association of Urology. Milan, Italy, 2013.
110. OnabotulinumtoxinA Significantly Decreases Urinary Incontinence and Provides Treatment Benefit in Patients with Idiopathic OAB: A Pooled Analysis of Two Phase III Placebo-Controlled Pivotal Trials. International Continence Society Annual Meeting. Barcelona, Spain. 2013.

111. International Validation of a Bladder Screening Tool for OAB. International Continence Society Annual Meeting. Barcelona, Spain. 2013.
112. Pivotal Phase III Study in OAB Patients with Urinary Incontinence Confirms OnabotulinumtoxinA 100U Significantly Improves OAB Symptoms and Patients' Quality of Life. Mid-Atlanta AUA Annual Meeting. White Sulfur Springs, WV. 2013.
113. Pivotal Phase III Study in OAB Patients with Urinary Incontinence Confirms OnabotulinumtoxinA 100U Significantly Improves OAB Symptoms and Patients' Quality of Life. New England AUA Annual Meeting. Hartford, Connecticut. 2013.
114. PTNS: Neuromodulation for the Masses. Orange County Urological Society Meeting. San Diego, CA. 2013.
115. Neuromodulation. Georgia Urological Association Annual Meeting. Sea Island, GA. 2013.
116. Mesh in Pelvic Floor Reconstruction. Georgia Urological Association Annual Meeting. Sea Island, GA. 2013.
117. Practical Urodynamics. Georgia Urological Association Annual Meeting. Sea Island, GA. 2013.
118. A Case-Based Approach to Treating OAB. AUA South Central Section Annual Meeting. Chicago, IL. 2013.
119. In Depth Consensus Panel on Third Line Therapies. Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Annual Meeting. Miami, FL. 2014.
120. Efficacy of Percutaneous Tibial Nerve Stimulation for OAB in a Community-Based Urology Practice. Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Annual Meeting. Miami, FL. 2014.
121. Refractory Overactive Bladder – Is This a Therapeutic Failure or a Different Disease? Northeastern Section AUA Annual Meeting. Jacksonville, FL. 2014.
122. Neuromodulation for OAB and NDO. Rodney Appell Memorial Update in Gynecologic Urology Annual Review Course. Miami, FL. 2015.
123. Barriers to Excellence in the Treatment of OAB. Rodney Appell Memorial Update in Gynecologic Urology Annual Review Course. Miami, FL. 2015.
124. AUA Guidelines and Treatment of UTI's. Rodney Appell Memorial Update in Gynecologic Urology Annual Review Course. Miami, FL. 2015.
125. Retropubic Urethropexy. Making a Comeback? Rodney Appell Memorial Update in Gynecologic Urology Annual Review Course. Miami, FL. 2015.
126. Urodynamics Prior to Anti-incontinence Procedures. Rodney Appell Memorial Update in Gynecologic Urology Annual Review Course. Miami, FL. 2015.

127. When I Die, You Die, The Fall of the American Health Care System. Rodney Appell Memorial Update in Gynecologic Urology Annual Review Course. Miami, FL. 2015.
128. The BESIDE Study. The Safety and Efficacy of Mirabegron Add-on Therapy to Solifenacin in Incontinent Subjects with an Inadequate Response to Initial 4-week Solifenacin Monotherapy. International Incontinence Society Annual Meeting. Montreal, Quebec. 2015.
129. The BESIDE Study. The Safety and Efficacy of Mirabegron Add-on Therapy to Solifenacin in Incontinent Subjects with an Inadequate Response to Initial 4-week Solifenacin Monotherapy. 35th Congress of the Society International Urology. Melbourne, Australia. 2015.
130. The BESIDE Study. The Safety and Efficacy of Mirabegron Add-on Therapy to Solifenacin in Incontinent Subjects with an Inadequate Response to Initial 4-week Solifenacin Monotherapy. AUA Annual Meeting. New Orleans, LA. 2015.
131. Neuromodulation for the Masses. Visiting Professor. UAMS Department of Urology. 2015.
132. Role of Urodynamics Prior to Surgery. Visiting Professor. UAMS Department of Urology. 2015.
133. Neuromodulation for the Masses. Arkansas Urological Society Annual Meeting. Little Rock, AR. 2015.

My signature verifies that the information on this curriculum vitae is accurate and updated annually.

Signature: _____

Date: _____